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Thrombus formation under high fluid shear rates at the site of atherosclerotic plaque 
rupture leads to myocardial infarction and stroke. At high shear rates, thrombus is formed 
by platelets adhering via the glycoprotein von Willebrand factor (vWF). To investigate the 
relative contributions of vWF and platelets in high shear thrombosis, the present work 
developed a microfluidic thrombosis assay to meet low blood volume requirements and 
fluid shear conditions (3500-6000 s-1). Microfluidic conditions were selected to mimic the 
high shear environment of a diseased coronary artery, with the long-term objective of 
developing a clinically relevant assay for the assessment of thrombosis risk and treatment 
efficacy. The microfluidic design also addressed the requirement for volumetric thrombus 
formation rather than only surface platelet adhesion. As part of the design of the 
microfluidic assay, the effect of flow pulsatility on high shear thrombosis was investigated. 
It was found that steady wall shear rate matched to the mean pulsatile wall shear rate 
reproduced bulk thrombus formation characteristics of occlusion time, lag time, and 
thrombus growth rate, allowing subsequent experiments and future device design to utilize 
steady flow. The microfluidic assay was implemented to study the roles of vWF and 
platelets to thrombus formation using blood analogs produced from whole human blood 
diluted with normal saline at 90% and 99%. Hematocrit was restored to normal in all cases 
with the addition of red blood cells, and vWF and platelets were selectively restored to 
normal levels. Results showed that 90% dilutions with only vWF restored to normal levels 
occluded in 6/7 subject tested. The addition of platelets accelerated thrombus formation, 
but blood analogs with only platelets restored to normal levels occluded in only 2/5 
xvii 
 
subjects, indicating that vWF is more contributory in high shear occlusive thrombosis. At 
99% dilutions, large thrombus formed with the addition of both platelets and vWF but was 
unstable and did not fully occlude the channel, indicating the possible requirement of an 
additional stabilizing factor(s) in occlusive thrombosis. Results of this study may lead to 
the development of improved anti-thrombotic treatments and improve patient care by 
providing a potential assay to evaluate treatment effectiveness and predict thrombosis risk. 
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CHAPTER 1: INTRODUCTION 
1.1  The Clinical Problem of Thrombosis 
Thrombosis is the pathological clotting of blood within a vessel. Thrombosis can lead to 
vessel occlusion, ischemia, and death. Biological mechanisms, namely the coagulation 
cascade and platelet aggregation, normally act in concert to prevent excessive bleeding in 
a process called hemostasis. However, the same mechanisms under pathological conditions 
result in thrombosis. In general, thrombosis results from the combination of 1) a 
thrombogenic surface, 2) abnormal fluid mechanic conditions, and 3) pro-thrombotic blood 
chemistry (Chung & Lip, 2003; Lowe, 2003). Often, a thrombogenic surface results from 
the disruption of the endothelial cells lining a blood vessel, but foreign surfaces, such as 
those of vascular grafts or prosthetic heart valves, may also initiate thrombosis. 
Pathologically elevated fluid shear rates result in thrombi composed primarily of platelets, 
known as “white clots.” In addition to platelets, plasma proteins, including coagulation 
factors, thrombin, fibrinogen, and von Willebrand factor (vWF) are critical for thrombosis, 
and their relative contributions depend on shear rate (Jackson, 2007). 
Platelet thrombus formation in the coronary arteries leading to myocardial 
infarction (MI) occurs under very high shear rates (Davies, Thomas, McMichael, & 
Richardson, 1981; Davies & Thomas, 1985; Falk, 1983; Friedman & van den Bovenkam, 
1966; Friedman, 1971). Occlusive thrombus formation can lead sudden cardiac ischemic 
death in less than an hour (Davies & Thomas, 1984). Given the substantial public health 
burden associated with MI, the study of thrombus formation at high shear rates, and in 




1.2  Characteristics of High Shear Thrombosis 
Fluid mechanic conditions determine the formation pathway and composition of thrombi. 
Wall shear rate has been identified as a critical fluid dynamic metric governing thrombus 
formation (Jackson, 2007; Maxwell et al., 2007). Wall shear rate, , is defined as the 








   (1-1) 
where Q is the volumetric flow rate and r is the tube radius. Shear rate, τ, is related to fluid 
shear stress through the fluid’s kinematic viscosity, , by 
    .  (1-2) 
At low shear rates (<500 s-1), thrombus formation is dominated by coagulation, 
leading to erythrocyte- and fibrin-rich thrombi or “red clots.” The medical condition of 
deep vein thrombosis exemplifies this process. Coagulation is the process by which the 
plasma protein fibrinogen is cleaved by thrombin to form fibrin, an insoluble protein that 
results in the formation of a gel-like structure. Thrombin formation is critical for 
coagulation and is generated via a cascade of coagulation factor interactions initiated by 
tissue factor, which is found in the extracellular matrix of blood vessels and is exposed by 
vessel injury.  
 Conversely, thrombus formation at high shear rates (>3500 s-1) is dominated by 
platelet aggregation, leading to “white clots.” MI is precipitated by platelet-rich thrombus 
formation at the site of atherosclerotic plaque rupture (Davies, Fulton, & Robertson, 1979; 
Davies & Thomas, 1984, 1985; Davies, 1994) under high shear rates (Bark & Ku, 2010). 
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The rapid time scales of occlusion combined with the observation of reocclusion despite 
full heparinization (Gold et al., 1986), indicate that platelet adhesion and aggregation, 
rather than coagulation, is the primary pathway of arterial thrombus formation. 
Additionally, a limited number of pathological specimens show platelet-rich thrombus 
formation at or near the sites of atherosclerotic coronary stenosis (Davies et al., 1981; 
Davies & Thomas, 1985; Falk, 1983; Friedman & van den Bovenkam, 1966; Friedman, 
1971), and platelet-rich emboli have been identified distal of atherosclerotic lesions (Falk, 
1985). These observations have led to a consensus that arterial thrombi associated with MI 
can be characterized at platelet-rich “white clots,” distinct from erythrocyte-rich “red clots” 
that occur in veins (Lippi, Franchini, & Targher, 2011; Lowe, 2003; Mackman, 2008; 
Rumbaut & Thiagarajan, 2010). 
 Occlusive platelet thrombosis has been studied in vitro by perfusing whole blood 
or platelet rich plasma through a test section at high shear rate. Studies have used 
cylindrical and parallel platelet perfusion chambers both with (Badimon, Badimon, Galvez, 
Chesebro, & Fuster, 1986; Barstad, Roald, Cui, Turitto, & Sakariassen, 1994; Ku & 
Flannery, 2007; Li, Ku, & Forest, 2012) and without a stenosis (Gutierrez et al., 2008; 
Hosokawa et al., 2011; Maloney, Brass, & Diamond, 2010; Neeves et al., 2008; Sixma, de 
Groot, van Zanten, & Ijsseldijk, 1998). Using  whole blood perfusion through a cylindrical, 
stenotic test section that closely mimics coronary artery geometry, Ku and colleagues have 
demonstrated that in vitro high-shear, platelet-rich thrombus formation is characterized by 
three phases (Wootton, Markou, Hanson, & Ku, 2001): Phase I, an initial deposition phase 
with limited thrombus growth, Phase II, rapid platelet accumulation (RPA), and finally 
Phase III, lumen occlusion (Ku & Flannery, 2007; Para, Bark, Lin, & Ku, 2011)  
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(Figure 1-1 and Figure 1-2). Thrombi formed in this system using lightly heparinized 




Figure 1-1: Characteristic thrombus volume growth under high shear rate, including initial 




Figure 1-2: In vitro thrombus formation in a stenotic glass capillary at an initial wall shear 
rate of 6500 s-1. The thrombus initially appears as a faint haze at the tube wall and grows 
to fully occlude flow. 
 
 
 The phases of occlusive thrombus formation may be quantified by initial deposition 
rate and/or lag time, RPA rate, and occlusion time. To describe Phase I of occlusive 
thrombosis, lag time has previously been defined as the time for the thrombus thickness to 
reach 10 m (Bark, Para, & Ku, 2012), though any definition of the transition from  
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Phase I to Phase II is somewhat arbitrary. Lag time has been shown to range from 175 to 
300 s for initial shear rates of 500-5000 s-1 (Bark et al., 2012), with initial deposition rates 
measures to be approximately 3×10-6 cm3/min at shear rates of 25,000 s-1 (Para et al., 2011). 
Lag time and slower initial platelet deposition rates are thought to represent the time 
necessary for plasma proteins, such as von Willebrand factor (see Section 1.5 for a detailed 
discussion), to be absorbed onto the collagen surface to support platelet adhesion (Neeves 
et al., 2013). Neeves et al. (2013) report a lag time (time for 1% surface coverage) of 
approximately 150 s-1 at a shear rate of 1500 s-1, and lag time is weakly correlated with 
vWF levels. Lag time and initial deposition rate may also reflect the time necessary for 
adherent platelets to activate, initiating a positive feedback for further platelet thrombus 
growth (Bark et al., 2012). Interestingly, lag time decreases with increasing shear rate (Bark 
et al., 2012), reflecting that protein absorption onto collagen (Schneider et al., 2007) and/or 
platelet activation (Holme et al., 1997; Ramstack, Zuckerman, & Mockros, 1979) is 
enhanced by shear rate.  
 Following initial deposition, Phase II of occlusive thrombus formation is 
characterized by rapid thrombus growth rates, quantified as RPA rate. For experiments 
with initial shear rates of approximately 25,000 s-1, RPA rates average 20×10-6 cm3/min, 
more than 6 times the rate of initial platelet deposition (Para et al., 2011). Phase II growth 
rates increase with increasing shear rates up to approximately 6000 s-1, with maximum 
growth rates at 6000-10 000 s-1, an order of magnitude greater than growth rates at 
physiological shear rates of 500-1500 s-1. Above 6000 s-1, thrombus growth rates more 
gradually decrease up to 100 000 s-1. Thrombus formation during RPA may be uneven, 
with “fingers” of thrombus protruding into the lumen. 
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 The growing thrombus ultimately leads to Phase III, the full occlusion of the test 
section and cessation of blood flow. Occlusion times of approximately 12-17 minutes have 
been measured in 70-83% stenoses of 1.5 mm test sections (Bark et al., 2012; Para et al., 
2011). Though occlusion time provides a bulk measurement occlusive thrombus formation, 
combining metrics representative of all three phases of platelet thrombus growth provide a 
more comprehensive description of occlusive thrombus formation relevant to MI that may 
ultimately prove useful for patient-specific measurement of high shear thrombotic 
potential. 
 
1.3  Fluid Mechanics of Healthy and Stenotic Arteries 
Blood flow in arteries is pulsatile, a consequence of cyclic cardiac pumping, with 
secondary flows developing at branches and curves. The coronary and carotid arteries are 
among the arteries most prone to disease, which leads directly to myocardial infarction and 
stroke, so we will focus the present discussion on flow features at these locations. The 
carotid arteries, which supply blood to the brain and face, have a unique bifurcation 
geometry with an expansion, or sinus, at the origin of the internal carotid. In combination 
with pulsatile flow, this geometry results in reversing velocity profiles along the outer wall 
and transient flow separation along the posterior wall (Ku, Giddens, Phillips, & Strandness 
Jr, 1985). The left coronary bifurcation is also characterized by complex, three-
dimensional, tortuous geometry that result in reversing and secondary flows (He & Ku, 
1996).  
 In both the coronary and carotid arteries, flow reversal and secondary flows result 
in low mean wall shear stress and wall shear oscillations. This type of flow regime has been 
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shown to induce atherosclerotic intimal thickening in a canine model (Salam, Lumsden, 
Suggs, & Ku, 1996). In contrast, most regions of the arterial tree maintain a wall shear 
stress of around 15 dyne/sm2 (Glagov, Zarins, Giddons, & Ku, 1988), or a wall shear rate 
of between 500 and 1500 s-1. As atherosclerotic lesions grow, the diameter of effected 
artery is reduced over a short distance, forming a stenosis. Clinically, percent stenosis is 
defined by percent reduction in diameter: 
  %  stenosis =
D1−D2
D1
× 100% (1-3) 
where D1 is the upstream diameter and D2 is the minimum diameter at the stenosis. As 
disease progresses, the minimum diameter decreases (percent stenosis increases). Fluid 
mechanically, the increase in percent stenosis results in higher wall shear rates (Bark & 
Ku, 2010) in accordance with eq. (1-1), which are present at the time of atherosclerotic 
plaque rupture and thrombosis.  
 Arterial flows are inherently pulsatile, but little work has been done to quantify the 
effect of flow pulsatility on thrombus formation, particularly at very high shear rates 
associated with arterial stenosis. One previous study (van Breugel, Sixma, & Heethaar, 
1988) showed no difference in platelet adhesion under steady flow conditions at shear rates 
from 0 to 1800 s-1 and non-reversing pulsatile with the same mean shear rate and increased 
platelet deposition with increasing amplitude for a mean shear rate of 0 s-1 (reversing flow). 
However, the shear rates investigated were much lower than expected in stenotic arteries, 
and reversing flow with non-zero mean shear rate was not considered, so platelet adhesion 
results may not be relevant to arterial thrombosis in stenotic arteries. Platelet adhesion 
under pulsatile flow at low shear rates (300-1300 s-1) was also studied by Zhao et al. (2008) 
at a frequency of 0.067 Hz, much lower than the frequency of arterial pulsatility. Thus, 
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thrombus formation under high shear (   > 3000 s-1), pulsatile flow (frequency > 1 Hz), 
similar to that found in stenotic arteries, should be investigated to ensure that in vitro 
conditions mimic pathological conditions relevant to MI. Alternatively, if flow pulsatility 
is found to have no effect compared to steady flow on the thrombus formation parameters 
of interest, studies may be performed under steady flow conditions, which are simpler to 
experimentally design and implement. 
 
1.4  Platelet Adhesion, Aggregation, and Accumulation 
Historically, platelet adhesion and aggregation were thought to be initiated by platelet 
adhesion to exposed collagen via integrin IIb3 (Jackson, 2007). In this model, collagen-
bound platelets are activated by soluble agonists, such as ADP, thrombin generated by 
simultaneous blood coagulation, and thromboxane A2. Platelet activation induces shape 
change and the release of - and dense-granule contents, including vWF, ADP, calcium 
ions, coagulation factors, and inflammatory factors, which in turn act to recruit and activate 
circulating platelets (Davi & Patrono, 2007). Activated platelets adhere to each other via 
IIb3 binding to fibrinogen. This process is exemplified by light transmission 
aggregometry, a platelet function test in which platelet rich plasma is stirred in the presence 
of a platelet agonist, and the formation of platelet aggregates alters the transmissivity of 
the suspension (Rechner, 2011). Though additional complexities, particularly with respect 
to the types of adhesive proteins involved, this model remains a accepted framework for 
platelet aggregation under low flow/low shear (<500 s-1) conditions. 
 Studies over the last 30 years have illustrated that platelet adhesion and aggregation 
under physiological shear rates (500-1500 s-1) are more complicated processes involving 
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1) additional adhesive proteins, particularly von Willebrand factor, 2) multiple stages of 
binding, and 3) an altered understanding of the role of platelet activation. Sakariassen et al. 
(1979) showed that the amount of vWF bound to extracellular matrix increased with plasma 
vWF concentration, and the number of adherent platelets also increased with the amount 
of bound vWF. However, that study utilized an average shear rate of only 805 s-1 and 
investigated platelet-surface adhesion and not large-scale platelet aggregation and 
accumulation (many more platelet-platelet adhesion events than platelet-surface adhesion 
events leading to thrombus growth beyond surface coverage). 
 A series of later studies indicate a two-stage model of high shear platelet adhesion 
in which platelets become tethered to extracellular matrix via vWF-GPIb bonds, reducing 
translocation speed and allowing firm adhesion via IIb3. Savage et al. (1996) showed that 
the number of platelets adhering to fibrinogen decreased with increasing shear rate, 
whereas the number of platelet adhering to vWF increased over the range of 50-1500 s-1. 
Platelets adhering to vWF tended to translocate in the direction of flow before firmly 
adhering, whereas platelets adhering to fibrinogen did not translocate. These results 
indicate that only vWF-GPIb binding has a sufficiently fast on-rate to initiate platelet 
tethering at shear rates greater than 1000 s-1 (Ruggeri, 2007). A subsequent study (Savage, 
Almus-Jacobs, & Ruggeri, 1998) in which blood was perfused over Type I collagen 
showed synergistic behavior of platelet adhesive substrates and receptors. Maxwell et al.  
(2007) demonstrated a similar two-stage process of platelet aggregation by perfusing whole 
blood over platelet monolayers in capillary tubes at 1800 s-1. To extend these studies to 
platelet adhesion to atheromatous plaque, Reininger et al. (2010) perfused whole blood 
over human plaque material at 1500 s-1. Results also indicate a two-stage thrombus 
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formation process, though with initial adhesion mediated by GPVI binding to collagen and 
stabilization via tissue factor mediated coagulation. 
 Several developments in the understanding of platelet activation have also 
increased the complexity of platelet aggregation under flow. In addition to soluble agonists, 
platelets have been shown to be activated by fluid shear stress (Holme et al., 1997; Jesty, 
Yin, Perrotta, & Bluestein, 2003; Ramstack et al., 1979). Additionally, Ruggeri  
et al. (2006) showed that at shear rates greater than 10 000 s-1, non-activated platelet form 
aggregates on immobilized vWF in the presence of plasma vWF. Recently, vWF was 
shown to be essential for platelet aggregation in vitro (Westein et al., 2013). 
 Taking the results for platelet aggregation under flow collectively, distinct high-
shear mechanisms are apparent, particularly above a shear rate of 10 000 s-1. Under these 
conditions, platelets become initially tethered to collagen via platelet  
glycoprotein Ib (GPIb) binding to immobilized vWF (Bergmeier, Chauhan, & Wagner, 
2008; Yago et al., 2008). Subsequently, rolling aggregates of non-activated platelets and 
vWF form (Jackson, 2007; Ruggeri et al., 2006). However, non-activated aggregates are 
not capable of forming large-scale stable thrombus, and activation of IIb3 appears to be 
necessary for occlusive thrombosis (Para, 2012). VWF-tethered platelets are then activated 
by shear rate, vWF binding, soluble agonists, or some combination of factors to initiate 
firm adhesion via IIb3. Studies also indicate that the growing thrombus under high shear 
may be stabilized by fibrinogen (Maxwell et al., 2007; Savage et al., 1998). Between 1000 
and 10 000 s-1 exists an intermediate range of platelet aggregation that involved platelet 
tethering via vWF and aggregate stabilization via fibrinogen and/or fibronectin to greater 
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or lesser extents (Jackson, 2007), though the relative contributions vWF, platelets, and 
fibrinogen are as yet unclear. 
 
1.5  Von Willebrand Factor in High Shear Thrombosis 
The studies outlined in the previous section indicate that vWF is essential for high shear 
thrombus formation. VWF undergoes a conformational change at shear rates >5000 s-1 that 
is thought to expose additional collagen- and platelet-binding sites. Plasma vWF 
concentration and activity have also been shown to be significantly higher in subjects with 
recurrent MI and first-ever ischemic stroke compared to control subjects (Bongers et al., 
2006; Jansson, Kilsson, & Johnson, 1991). Together, these data indicate that vWF may 
play critical role in thrombus formation related to MI and stroke. 
 Von Willebrand factor (vWF) is a multimeric glycoprotein essential in hemostasis 
and implicated in atherothrombosis. VWF is found in blood plasma, platelet -granules, 
and the extracellular matrix of blood vessels. The fundamental subunit of vWF multimers 
is a dimer, each component of which is composed of 14 domains: D1-D2-D’-D3-A1-A2-
A3-B1-B2-B3-C1-C2-CK. Dimers are assembled tail-to-tail at the CK domain, and the 
vWF multimers are subsequently assembled head-to-head at the D1 domain to form “ultra-
large” long chain molecules (Sadler, 1998) of lengths between 100 and 1000 m (Springer, 
2011). Ultra-large vWF is subsequently cleaved at the A2 domain by ADAMTS13 to about 
15 m in the normal circulation (Schneider et al., 2007). VWF binds to collagen via the 
A3 domain, platelet receptor GPIb via the A1 domain, and platelet integrin IIb3 at the 
C1 domain.  
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 VWF has been shown to undergo a conformational change modulated by shear 
(Siedlecki et al., 1996). Under low shear, vWF assumes a globular form and at high shear 
is elongated. Recently, Colace and Diamond (2013) showed formation of long fibers or 
nets of vWF in whole flowing blood at shear rates >25 000 s-1. In addition to modeling 
shear unfolding of vWF, Schneider et al. (2007) showed that vWF adsorption onto collagen 
is enhanced at high shear rates (>5000 s-1). These results indicate that vWF unfolding 
exposes binding sites that are important for platelet adhesion. Additionally, vWF 
elongation exposes sites for multimer cleavage by protease ADAMTS13 (Dong, 2005). 
 Quantitative or qualitative defects in vWF or its protease, ADAMTS13, result in 
bleeding and thrombotic disorders. Von Willebrand disease (VWD) is defined as a 
quantitative deficiency of vWF (Type 1 and Type 3) or by qualitative abnormalities in 
vWF structure and function (Type 2) resulting in a decreased capability to form hemostatic 
platelet plugs. Von Willebrand Disease (VWD) is the most common inherited bleeding 
disorder in children (Rodeghiero, Castaman, & Dini, 1987). The symptoms of VWD 
include nose bleeding, skin bruises and hematomas, prolonged bleeding from trivial 
wounds, oral cavity bleeding, and excessive menstrual bleeding (Sadler et al., 2000). 
ADAMTS13 deficiency has been linked to thrombotic thrombocytopenia purpura (TTP), 
a disorder characterized by decreased platelet count, platelet thrombosis of the 
microvasculature, and skin rash due to bleeding under the skin (Bianchi, Robles, Alberio, 
Furlan, & Lämmle, 2002; Furlan et al., 1997). ADAMTS13 deficiency results in higher 
than normal concentrations of circulating ultra-large vWF (ULVWF) multimers. ULVWF 
has a higher affinity for platelet binding, and thus platelets are scavenged from circulation 
and form micro-thrombi, resulting in the symptoms of TTP. 
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 As discussed above, vWF is thought to be the primary protein responsible for high 
shear platelet binding. Wellings and Ku (2012) modeled platelet capture via vWF under 
very high shear (10 000 to 500 000 s-1) assuming that only A1 domains on the outside of 
globular vWF were available to bind platelets, with more A1 domains exposed as vWF 
elongates under shear. Given the high shear conditions leading to large drag forces on 
adhering platelets and short exposure times of platelet GPIb to vWF-A1, the authors 
conclude the following conditions necessary for platelet capture at shear rates greater than 
50 000 s-1: multiple GPIb-vWF bonds, vWF unfolding, formation of concave vWF nets, 
and GPIb-(vWF-A1) on-rates greater than 108 M-1s-1. All but the final conclusion require 
vWF unfolding for high shear platelet capture and indicate that vWF-A1 availability is the 
critical factor in high shear platelet capture and thrombus growth. Additionally, modeling 
showed that local vWF concentration must be elevated by the vWF release from platelets. 
 
1.6  Summary of High Shear Thrombus Formation 
Taking the information presented in the preceding sections together leads to a model of 
high shear thrombosis outlined in Table 1-1 and Figure 1-3. First, atherosclerotic plaques 
form stenotic regions that induce high fluid shear rates (Figure 1-3A). Plaque cap rupture 
exposes a thrombogenic surface supporting thrombus initiation. The high shear region 
caused by the stenosis induces vWF unfolding (Figure 1-3B). Elongated vWF nets are 
adsorbed onto the surface and form nets (Figure 1-3C). Enhanced platelet diffusivity and 
margination act to move platelets to the vessel wall (Figure 1-3D) where they reversible 
bind to surface-bound vWF (Figure 1-3E). After adhesion, platelets activate, likely by a 
combination of binding, soluble agonists, and high shear. Activation leads to irreversible 
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binding via αIIbβ3 and release of platelet granule contents, including vWF, which locally 
increases the vWF concentration at the site of thrombosis (Figure 1-3F). This process 
initiates a positive-feedback system that results in billions of platelets rapidly binding and 
activating, leading to very rapid thrombus growth (Figure 1-3G to J). However, it is unclear 
what the relative contributions of vWF and platelets are to the process of high shear 
thrombosis or what the minimum necessary concentrations are. Furthermore, the roles of 
plasma vWF and platelet vWF remain to be determined (Jackson, 2007). A better 
understanding of the contributions of vWF and platelets in high shear thrombus formation 
may lead to better therapeutic targets to prevent arterial thrombosis. 
 
 
Table 1-1: Process of High Shear Thrombus Formation 
1 Regions of stenosis induce high wall shear rates. 
2 vWF unfolds in high shear regions. 
3 Unfolded vWF is adsorbed onto non-endothelialized surfaces. 
4 
Shear enhanced diffusivity induces platelet margination and transports platelets to 
the exposed surface. 
5 Non-activated platelets bind to surface-bound vWF. 
6 
Activation of adhered platelets by shear and/or soluble agonists releases large 
amount of vWF locally and activates αIIbβ3 for firm adhesion. 
7 
vWF nets form on the growing thrombus as platelets are continually captured and 
activated. 
8 
The vWF nets rapidly capture billions of platelets with large thrombus formation, 





Figure 1-3: Summary of high shear thrombosis. (A) Stenotic regions induce wall high shear 
rates, (B) high shear conditions result in vWF elongation, (C) vWF is adsorbed to non-
endothelialized surfaces, (D) enhanced diffusivity and platelet margination transport 
platelets to the vessel wall, (E) non-activated platelets bind to vWF, (F) platelet activation 
releases of granule contents and activates αIIbβ3, (G-H) vWF is adsorbed to the growing 
thrombus, and platelets are continually captured and activated, (I) large-scale thrombus 




Figure 1-3 cont.: Summary of high shear thrombosis. (A) Stenotic regions induce wall high 
shear rates, (B) high shear conditions result in vWF elongation, (C) vWF is adsorbed to 
non-endothelialized surfaces, (D) enhanced diffusivity and platelet margination transport 
platelets to the vessel wall, (E) non-activated platelets bind to vWF, (F) platelet activation 
releases of granule contents and activates αIIbβ3, (G-H) vWF is adsorbed to the growing 
thrombus, and platelets are continually captured and activated, (I) large-scale thrombus 




1.7  Predicting and Preventing Thrombosis 
Despite the high population rates of MI and stroke, individual prediction remains elusive. 
Though a number of systemic risk factors have been identified, including age, weight, 
blood pressure, cholesterol levels, and diabetes, a European Society of Cardiology 
proposed 10-year risk score gives results between 0% and ~50% (Perk et al., 2012; Smith 
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et al., 2001). Severe coronary or carotid stenosis are linked to increased risk of stroke 
(Autret et al., 1987; Ellis et al., 1988), but when specific arterial lesions are assessed, 
medically treated patients have individually low rates of MI and stroke. One study showed 
patients with severe stenosis (>50%) of the left anterior descending coronary artery had a 
three-year risk of anterior MI of 6-11%, and patients with very severe stenosis (>90%) had 
a 15% risk of anterior MI. Equally noteworthy, patients with less than 50% stenosis had a 
2% risk of anterior MI (Ellis et al., 1988). A separate study similarly showed that that two-
year risk of ischemic stroke in patients with severe carotid stenosis (>70%) was 10-20%, 
and patients with mild to moderate stenosis had rates of 5-10% (Rothwell, Gibson, & 
Warlow, 2000). 
 Since evidence implicates shear induced platelet accumulation in MI and ischemic 
stroke, anti-platelet therapies (e.g. aspirin, clopidogrel/Plavix®) to prevent ischemic events 
(CAPRIE Steering Committee, 1996; Lewis et al., 1983) and platelet function testing to 
assess efficacy have been developed (Kundu, Heilmann, Sio, Garcia, & Ostgaard, 1996; 
Lordkipanidze et al., 2007; Rechner, 2011). However, evidence has also emerged that 5 to 
25% of patients are not responsive to aspirin therapy (Gum, Kottke-Marchant, Welsh, 
White, & Topol, 2003; Hovens et al., 2007) based on light transmission aggregometry and 
point-of-care platelet function tests, including PFA-100® (see Section 1.7.1), and aspirin 
resistance increases the risk of ischemic events (Krasopoulos, Brister, Beattie, & 
Buchanan, 2008; Snoep, Hovens, Eikenboom, Van der Bom, & Huisman, 2007; Sofi, 
Marcucci, Gori, Abbate, & Gensini, 2008), though existing tests give disparate results for 
patient-specific aspirin resistance (Lordkipanidze et al., 2007). Limited data also suggests 
that 5-10% of patients are non-responsive to clopidogrel (Michos, Ardehali, Blumenthal, 
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Lange, & Ardehali, 2006). Thus further methods for patient risk stratification may be useful 
to guide and assess therapy. 
 
1.7.1 Clinically Available Thrombosis Test Systems 
Currently available clinical platelet function tests may not adequately test the platelet 
accumulation pathways most relevant to MI and stroke. Most assays do not test platelet 
aggregation under flow, and none provide continuous analysis of thrombus growth. 
Presently, at least four platelet function tests are marketed for clinical use: light 
transmission aggregometry (LTA), PFA-100® (Siemens Corp.; Munich, Germany), 
Chrono-log Whole Blood Aggregometer (Chrono-log Corp.; Haverton, PA), VerifyNow® 
(Accumetrics, San Diego, CA). LTA, VerifyNow®, and the Chronolog Whole Blood 
Aggregometer utilize light transmission or impedance to measure platelet aggregation in 
response to platelet agonists under static flow conditions. LTA requires the use of platelet 
rich plasma (Rechner, 2011), while VerifyNow®  and Chrono-log uses whole blood 
(Lordkipanidze et al., 2007), but neither system simulates the high shear environment of 
arterial stenosis and therefore results may not be relevant to arterial thrombosis leading to 
MI and ischemic stroke.  
 The PFA-100® system perfuses a whole blood sample through a membrane orifice 
coated with fibrillar Type I collagen and epinephrine or ADP (Kundu et al., 1995; Kundu 
et al., 1996). The time to orifice closure is used as the test endpoint. Though this system 
results in high shear (~6000 s-1) platelet adhesion and aggregation, the fluid mechanics of 
flow through an orifice, with near zero shear before the orifice and a very short region  
(150 m) of elevated shear, are substantially different from flow in a stenotic artery, which 
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is characterized by a region of normal physiological shear rate (500-1000 s-1) followed by 
a region of elevated shear rate. Additionally, rather than using only collagen to support 
platelet adhesion and activation, the membrane is also coated with potent platelet agonists 
that affect individual activation pathways and may cause the results to differ from in vivo. 
The PFA-100® also does not allow the quantification of thrombus growth during the test. 
Thus, none of the currently available clinical methods for platelet function analysis utilize 
test conditions relevant to high shear occlusive thrombus formation and simulate arterial 
fluid mechanics, especially shear rate, or give insight into how high shear thrombus forms 
in real time. Furthermore, these tests and others give disparate results when used to assess 
patient-specific aspirin resistance (Lordkipanidze et al., 2007), and it is unclear which, if 
any, of the results are most relevant to thrombosis leading to MI and stroke. 
 VWF mediated platelet aggregation is currently measured using a ristocetin 
cofactor assay (VWF:RCo). Ristocetin, a now-unused antibiotic, induces vWF-mediated 
platelet agglutination via a presently unknown mechanism (NHLBI von Willebrand 
Disease Expert Panel, 2007), though results of VWF:RCo have been shown to correlate 
with shear dependent platelet-vWF interactions (Dong, 2001). In addition to not simulating 
physiological platelet-vWF binding, VWF:RCo exhibits very high variability (coefficient 
of variation ≥ 30%). Thus improved platelet function tests for vWF mediated platelet 
aggregation may be useful in clinical practice. 
 Based on the recommendations of a report (Zwaginga et al., 2006) from the 
International Society of Thrombosis and Haemostasis (ISTH), a more robust platelet 
function test relevant to arterial thrombosis at the site of stenosis should meet the following 
criteria: 1) limited blood volume, 2) a non-invasive method with bed-side/point-of-care 
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readouts for broad applicability in a clinical setting, 3) real-time monitoring of thrombus 
formation, 4) quantification of embolization, 5) use of a reproducible thrombogenic 
surface, 6) use of controlled shear rates applicable to arterial thrombosis, 7) sensitivity to 
thrombotic disorders and anti-thrombotic drugs and drug efficacy, 8) capability to monitor 
platelet inflammatory signatures. In addition to these requirements, we also suggest that an 
appropriately sized test section should be used to ensure many more platelet-platelet 
adhesion events than platelet-surface adhesion events. For the monitoring of platelet 
function associated with MI and stroke, since platelet accumulation appears to depend 
strongly on shear rate, the non-stenotic and stenotic shear rates in the microfluidic test 
section were designed to fall in the range of normal arteries (500-1000 s-1) and in the range 
of coronary and carotid stenosis (5000-10 000 s-1). Since experimental evidence suggests 
that maximum platelet deposition rates occur at approximately 6000 s-1, this shear range 
was targeted as an advantageous test shear rate to simulate worst-case thrombus formation. 
To simulate atherosclerotic plaque cap rupture, we use collagen Type I without additional 
agonists or coagulation factors as the prothrombotic surface. No presently marketed 
platelet function test meets all of these test requirements. Only the PFA-100® employs 
arterial shear rates; LTA, VerifyNow®, and the Chronolog whole blood analyzer all assess 
platelet function only in static blood. However, PFA-100® does not allow for real-time 
thrombus monitoring or embolus detection, and the shear rates are not well controlled due 
to its use of flow through an orifice. The present study endeavored to develop the test 
section of a robust laboratory high shear platelet function test that better meets these 
requirements by providing for well-controlled shear rates throughout the test section and a 
non-contact thrombus detection method that provides information about thrombus growth 
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and embolization for future development into a clinical assay for routine platelet function 
analysis. 
 
1.7.2 Microfluidic Thrombosis Assays in the Research Laboratory 
Microfluidic test sections are a rapidly emerging design for high shear platelet testing. 
Microfluidic test sections are a rapidly emerging design for high shear platelet testing. 
Microfluidic test sections have the advantage of requiring lower flow rates to produce the 
same wall shear rates as larger devices, thus requiring smaller overall blood volumes. This 
is particularly attractive for small animal studies, high throughput studies with human 
blood, and clinical testing of high shear platelet function and thrombus formation. Most 
microfluidic systems use rectangular cross sections (Colace, Muthard, & Diamond, 2012; 
Gutierrez et al., 2008; Hosokawa et al., 2011; Hosokawa et al., 2012; Maloney et al., 2010; 
Neeves et al., 2008), which apply only a single shear rate over their whole length, and fail 
to simulate the shear experienced by a platelet flowing in a normal arterial section and 
entering and exiting a stenotic, atherosclerotic section. Recently, a multipath microfluidic 
test device with a stenotic test section was developed by Li, Ku, and Forest (2012). This 
design meets many of the physiological/pathological design elements noted above, but it 
is relatively large for a microfluidic device (test section w × h = 750 × 250 m) and requires 
4-6 mL of blood for occlusion at shear rates of 7000-10 000 s-1, which is large compared 
to a standard blood draw of 10 mL, particularly if multiple tests are required. Future high-
shear thrombosis test devices should aim to reduce the required blood volume and 
streamline fluid handling to enable routine thrombosis testing. In the present study, a 
smaller microfluidic test section requiring less than 10 mL of blood for 3 tests was designed 
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along with a fluid handling system that minimized blood transfers and provides for high 
throughput. This test bed allowed for the subsequent aims to be performed with a 
reasonable (<10 mL) amount of human blood and provide the framework for a future 
commercial device. 
 
1.8  Summary, Hypothesis and Specific Aims 
Myocardial infarction (MI) and ischemic stroke result from the formation of occlusive 
thrombosis at the site of atherosclerotic plaque rupture at very high shear rates  
(5000 to >10 000 s-1). In general, thrombosis results from the combination of 1) abnormal 
fluid mechanic conditions, 2) a thrombogenic surface, and 3) pro-thrombotic blood 
chemistry. In the case of MI and ischemic stroke, plaque formation leads to stenosis, 
resulting in a region of very high fluid shear rate, which enhances platelet thrombus 
formation. When plaque rupture exposes the pro-thrombotic collagen, thrombosis may 
occur. Even in patients with arterial stenosis, prediction of MI and ischemic stroke remains 
elusive, indicating that pro-thrombotic blood chemistry may be an important risk factor. 
Still, few studies have endeavored to characterize the effect of plasma protein 
concentrations on high shear thrombus formation. 
 Platelet adhesion to collagen via blood glycoprotein von Willebrand Factor (vWF) 
is important for thrombosis initiation at high shear. VWF is a shear-sensitive multimer that 
transitions from a globular to elongated conformation under high shear rate, enhancing 
absorption onto a collagen surface and platelet adhesion. Furthermore, computational 
modeling of bonding kinetics indicates that vWF unfolding and net formation may be 
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essential for thrombosis at very high shear rate, indicating that vWF configuration and 
vWF-A1 availability may be the rate-limiting factors in high shear thrombosis.  
 The objective of the present study was to quantify the role vWF in thrombus 
formation using a microfluidic test system. The long term goal of this project is to assess 
patient risk of MI and ischemic stroke based on individual blood chemistry and identify 
potential therapeutic targets. The hypothesis of this study is that the rate of shear induced 
platelet accumulation depends on vWF-A1 availability determined by plasma vWF 
concentration. To address this hypothesis, the following specific aims were executed: 
 
Specific Aim 1: Assess the effect of flow pulsatility on shear induced platelet 
accumulation. Flow conditions, particularly shear rate, modulate platelet accumulation, 
but the effects of arterial pulsatile flow conditions are not well established. In this aim, 
whole porcine blood was be perfused through collagen-coated stenotic test sections under 
1 Hz pulsatile condition generated by a custom pressure driven experimental apparatus 
corresponding shear-matched steady conditions (~3800, 6500, and ~16 000 s-1). Time to 
occlusion, lag time, thrombus growth rate were obtained from microscopy images and 
compared between conditions. Results of this aim provide important design considerations 
for the high shear occlusive thrombus test described in the following aim. 
 
Specific Aim 2: Develop a high-shear, whole blood device for assessing arterial 
thrombosis potential. The device should require less than 10 mL of blood and provide 
high throughput for laboratory personnel. A microfluidic test cartridge was be 
developed based on the need for an efficient, low volume assay to evaluate patient risk for 
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thrombotic occlusion based on thrombus growth rate and time to occlusion. Design 
parameters include shear rate, blood volume, known thrombus growth characteristics, and 
manufacturing considerations. The test section was characterized by assessing thrombus 
formation in a normal population, providing a robust microfluidic platform for the 
subsequent aim. 
 
Specific Aim 3: Demonstrate that thrombus formation at very high shear rates 
requires a minimum plasma vWF concentration to initiate thrombus growth and 
vWF release from platelets for large-scale accumulation. Though individual plasma 
proteins have been implicated in arterial thrombosis, the effects on shear induced platelet 
accumulation of below-normal plasma vWF concentrations and vWF-deficient platelets 
have not been previously studied. To show that SIPA is limited by the availability of vWF 
rather than other blood proteins and constituents, dilutions of whole human blood with 
normal hematocrit and ranges of platelet counts and vWF concentrations were perfused 
through the test section developed in Specific Aim 2 at shear rates of 6000 s-1. Microscopy 
images of thrombus formation were acquired throughout the experiments and time to 
occlusion was determined by measuring flow rate through the test section. A regression 
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CHAPTER 2: HIGH SHEAR THROMBUS FORMATION UNDER PULSATILE 
AND STEADY FLOW 
2.1  Introduction 
Myocardial infarction is precipitated by platelet-rich thrombus formation at the site of 
atherosclerotic plaque rupture (Davies, Fulton, & Robertson, 1979; Davies & Thomas, 
1984, 1985; Davies, 1994) under high shear rates (>3500 s-1)  (Bark & Ku, 2010). 
Thrombus formation can fully occlude the vessel and can lead to sudden cardiac ischemic 
death in less than an hour (Davies & Thomas, 1984). In pursuit of a greater understanding 
of thrombus formation mechanisms, many investigators have studied platelet adhesion and 
aggregation in vitro under steady flow conditions (Badimon, Badimon, Galvez, Chesebro, 
& Fuster, 1986; Badimon & Badimon, 1989; Barstad, Roald, Cui, Turitto, & Sakariassen, 
1994; Colace, Jobson, & Diamond, 2011; Gutierrez et al., 2008; Hosokawa et al., 2011; 
Houdijk, de Groot, Nievelstein, Sakariassen, & Sixma, 1986; Li, Ku, & Forest, 2012; 
Mailhac et al., 1994; Maloney, Brass, & Diamond, 2010; Neeves et al., 2008; Sakariassen, 
Aarts, & de Groot, 1983; Sixma, de Groot, van Zanten, & Ijsseldijk, 1998; Zhao et al., 
2008).  
  Platelet deposition under high shear rates is thought to be mediated by platelet 
glycoprotein Ib (GPIb) binding to immobilized von Willebrand factor (vWF) on a 
thrombogenic surface, e. g. collagen (Ruggeri, 2007; Savage, Saldivar, & Ruggeri, 1996). 
Subsequent platelet activation results in firm adhesion via integrin IIb3 (Epstein, 
Lefkovits, Plow, & Topol, 1995). Platelet deposition has been shown to depend on shear 
rate. Specifically, platelet adhesion and accumulation rates increase with shear rate up to 
1500 and 6000 s-1, respectively (Bark, Para, & Ku, 2012; Savage et al., 1996).  
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 Most previous studies have investigated thrombus formation under flow conditions 
with shear rates of less than 1500 s-1, and nearly all utilized steady flow. However, flow in 
arteries is pulsatile with a frequency of approximately 1 Hz, and stenotic geometry induces 
shear rates of well over 1500 s-1 (Bark & Ku, 2010). Since platelet deposition depends on 
shear rate under steady conditions (Bark et al., 2012), it is reasonable to question whether 
unsteady time variations in pulsatile shear rate may also affect thrombus growth. A small 
number of studies have investigated platelet deposition under pulsatile flow. Van Breugel 
et al. (van Breugel, Sixma, & Heethaar, 1988) investigated platelet adhesion using an 
annular perfusion chamber under mean shear rates ranging from 0 to 1800 s-1, amplitudes 
of 75 to 1000 s-1, and frequencies of 0.5 to 2 Hz. Results indicated no significant difference 
in platelet adhesion per unit area between pulsatile and steady flow for mean shear rates 
>0 s-1, and results show increased platelet adhesion with increasing amplitude for a mean 
shear rate of 0 s-1. The flow conditions utilized by Van Breugal and colleagues yield shear 
rates much lower than those expected in stenotic coronary arteries, and their experimental 
apparatus did not allow for reversing flow for non-zero mean shear rates (Ku, 1997). The 
deviation of the experimental shear waveform from expected pathological conditions may 
lead to platelet adhesion results that are not relevant to coronary thrombosis at the site of 
atherosclerotic stenosis. In a more recent study, Zhao et al. (Zhao et al., 2008) investigated 
the effect of pulsatility on platelet adhesion at steady shear rates of 300 s-1 and 1300 s-1 and 
under a pulsatile condition which alternated between the two shear rates at a frequency of 
0.067 Hz (30 s period). In this case, platelet adhesion was shown to increase at a steady 
shear rate of 1300 s-1 compared to 300 s-1, and pulsatile flow resulted in the highest level 
of platelet adhesion studied, conflicting with the observations of van Breugel et al. The 
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relevance of the Zhao results to coronary thrombosis is questionable as the pulse frequency 
used was considerably less than that of the coronary arteries, and the shear rates were lower 
than expected in coronary stenosis. 
 The objective of the present study is to quantify the effect of reversing pulsatile 
flow relevant to the very high shear conditions present in coronary stenoses on platelet 
accumulation leading to formation of an occlusive thrombus. A tubular stenotic test section 
(Ku & Flannery, 2007; Para, Bark, Lin, & Ku, 2011) was adapted for use with a pulsatile 
flow apparatus. Thrombus growth rate, time to occlusion, and lag time were quantified 
under a surrogate coronary artery pulsatile shear waveform, and under steady flow 
conditions corresponding to the mean and maximum pulsatile shear rates. Results of this 
study may be applied to the design of flow-based thrombosis assays, specifically to assess 
whether a simpler steady flow system yields comparable results to more complicated 
pulsatile flow systems. 
 
2.2  Methods 
2.2.1 Experimental Apparatus 
Whole porcine blood was obtained from a local abattoir (Holifield Farms, Covington, GA) 
and lightly heparinized at 3.5 USP units/mL, as previously described (Para et al., 2011). 
Porcine blood has red blood cell count of 5.37 ± 0.74 × 106 /μL  and platelet count of  
407 320 ± 121 240 /uL, on average (Velik-Salchner et al., 2006). A sample from the farm 
pigs used in this study showed a red blood cell count of 5.9 × 106 /μL and a platelet count 
480 000 /μL, both comparable to the literature values. For steady flow experiments, blood 
was perfused through the experimental apparatus described by Ku and Flannery (Ku & 
Flannery, 2007) (Figure 2-1a). Briefly, stenotic glass test sections were fabricated by a 
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professional glass blower, and test sections were selected for 77-79% stenosis by diameter, 
yielding a minimum throat diameter of 315-345 m. Test sections were incubated with 
0.1% collagen (Chronopar; Chronolog, Inc.; Havertown, PA) for 24 hours before 
experimentation. After rinsing with PBS, the test section was installed downstream of a 




Figure 2-1: Experimental apparatus for (a) steady and (b) pulsatile flow conditions 
 
 
 Steady flow experiments were performed under three shear rates, ~16 000 s-1, 
~3800 s-1, and ~6500 s-1, corresponding to the estimated maximum and mean expected 
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shear rates, as well as an intermediate flow condition, under pulsatile flow conditions. The 
intermediate flow condition corresponds to a previously measured range of fastest platelet 
thrombus growth (Bark et al., 2012). For each condition, the nominal shear rate is the initial 
shear rate at the throat of the stenosis. The shear rate throughout the experiment decreases 
as the growing thrombus increases the resistance of the test section, resulting in decreased 
flow rate with the same pressure head, according to Poiseuille’s law. Using the calculation 
of enhanced platelet diffusivity of Zydney and Colton (Zydney & Colton, 1988), the 
Schmidt numbers under these flow conditions are between 37 and 154, and the Peclet 
numbers are between 2618 and 2664. See Section 2.6 for more detailed treatment of the 
calculations for the Reynolds, Peclet, and Schmidt numbers. Blood flow out of the test 
section was measured using an electronic balance (HCB 302; Adam Equipment Co.; 
Danbury, CT) and recorded using Labview (National Instruments Corp.; Austin, TX). Time 
to occlusion, tocc, was defined as the time at which the mass no longer changed for at least 
2 minutes. 
 Pulsatile flow was achieved by having blood flow from a fixed upstream pressure 
head, through the test section, and into a sealed 250 mL flask (Figure 2-1b). The stopper 
of the flask was fitted with a 30 mL (1 oz.) bulb syringe, which was compressed using a 
rotating cam to modulate the downstream pressure. The cam was machined in-house with 
a circular profile with a diameter of 1.60 in. (40.6 mm) and a shaft offset of 0.20 in.  
(5.1 mm) to achieve the desired compression of the bulb syringe. The shaft was machined 
to interface with the drive of a peristaltic pump and controller (Masterflex L/S, model 
number 77300-40; Cole-Parmer; Vernon Hills, IL). In this way, the pressure difference 
across the test section was modulated to produce pulsatile flow at 1 Hz. The upstream 
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reservoir was connected to the test section via 49 cm of 1.6 mm ID Tygon tubing 
(Masterflex L/S 14; Cole-Parmer; Vernon Hills, IL), and the test section was connected to 
the flask by 37 mm of the same tubing. The pressure immediately downstream of the test 
section, p2 was measured using a pressure transducer (#60-3002; Harvard Apparatus; 
Holliston, MA) and recorded using Labview. The remaining volume in the upstream 
reservoir was measured visually and recorded every 30 seconds, and tocc was defined as the 
time after which the volume no longer changed for at least 2 minutes. 
 Microscopy images of thrombus formation were recorded during experimentation 
at 5 Hz using a high resolution CCD (Pixelfly; PCO; Kelheim, Germany) attached to a 
stereo microscope at 2.5x zoom (Stemi 2000-C; Carl Zeiss; Oberkochen, Germany). Image 
recording was facilitated by the Manager platform (Edelstein, Amodaj, Hoover, Vale, & 
Stuurman, 2010). The test section was immersed in a water-glycerol solution with 
refractive index matched to that of glass to reduce optical distortions, and the microscope 
was focused at the midline of the test section. 
 
2.2.2 Calculation of Shear Rate 
For all calculations, flow within the stenosis throat was approximated as Poiseuille flow, 
since the Reynolds number was less than 100 and the Womersley number was less than 1. 









    (2-1) 
where Q is the volumetric flow rate and r is the test section radius. Since eq. (2-1) is used 




decrease as thrombus forms in the test section. Q is related to the pressure drop, Δp, through 
the hydraulic resistance, Rh¸ using the equation 
  hRtQtp )()(  . (2-2) 
 Prior to experimentation, the total resistance of the test section and connecting 
tubing was calculated by flowing an approximately 35% by volume glycerol-water mixture 
with a viscosity of 3.0 × 10-3 Pa-s (comparable to a reference whole blood viscosity of  
3.24 × 10-3 Pa-s (Merrill, 1969)) through the system at a range of Δp and measuring the Q. 
For resistance calculations, a constant blood viscosity was assumed. Though the bulk 
apparent viscosity decreases with increasing shear rate, the apparent viscosity of whole 
blood is constant at between 3 × 10-3 Pa-s and 4 × 10-3 Pa-s for shear rates greater than  
10 s-1 (Replogle, Meiselman, & Merrill, 1967), which includes the full range of the 
experimental apparatus. The local viscosity immediately adjacent to the wall is likely lower 
due to the formation of a plasma skimming layer, but since it is difficult to assign a value 
to the wall viscosity, and since hydraulic resistance is a bulk parameter, the estimation of 
bulk apparent blood viscosity was used. From the resistance, the required Δp necessary to 
obtain the desired steady shear rates were calculated. For pulsatile flow, the required 
increased in upstream pressure to induce pulsatility was calculated to induce the desired 
pulsatile waveform. Following experimentation, measurements of downstream pressure 
were used in combination with the known upstream pressure head to calculate the 




2.2.3 Automated Image Processing 
An automated image processing algorithm, outlined in Figure 2-2, was developed in 
Matlab (R2012a; The Mathworks, Inc.; Natick, MA) to enhance and accelerate analysis of 
microscopy images (see APPENDIX A for code). The objective of this analysis was to 
obtain an estimate of thrombosis volume in each image. For each experimental condition, 
a 1.5 mm wide region of interest centered at the stenosis throat was selected. Next a 
reference image was identified in which no visible thrombus was observed. In the reference 
image, the outer edges of the stenosis within the region of interest were identified using a 
Laplacian of Gaussian filter (Marr & Hildreth, 1980). Following a global brightness 
correction to account for variations in illumination intensity, the reference image was 
subtracted from all subsequent images to highlight regions of thrombus growth. All pixels 
in the image were then classified as either thrombus or non-thrombus based on a user 
defined threshold to generated a binary image. For this study, the threshold was selected as 
10% of the maximum intensity change from the reference image to the last image in the 
sequence, acquired approximately 2 minutes after occlusion. From the binary image, the 
maximum and minimum extents of the thrombus were identified. The thrombus and 
stenosis edges were then used to calculate the stenosis lumen diameter, Do, and the 
thrombus lumen diameter, Di, at each pixel column. The volume, V, of the growing 
thrombus in each image was approximated using a semi-axisymmetric assumption (Para et 
al., 2011), such that 


























where w is the width of each pixel. All measurements were then converted to m and m3 
using the known non-stenotic capillary diameter as a reference. From plots of V versus 
time, t, thrombosis formation was characterized by computing lag time, tlag, and the rate of 
thrombus growth, dV/dt. The time to reach an initial deposition volume of 106 m3 was 
defined as tlag, and dV/dt was calculated as the slope of a linear fit of all points from tlag to 
tocc. Metrics were compared between experimental conditions using paired and unpaired  
t-tests, as appropriate, with statistical significance defined as p < 0.05. 
 
 






2.3  Results 
2.3.1 Pulsatile Flow Characteristics 
A characteristic shear rate waveform at the throat of the stenosis is shown in Figure 2-3 
both in detail (Figure 2-3a) and over the full experiment (Figure 2-3b). The waveforms 
show a pulse frequency of approximately 1 Hz with a large amplitude modulation of shear 
rate, including instances of negative shear rate resulting from backward flow (Figure 2-3a), 
consistent with coronary flow in a stenosis (Ku, 1997). The waveform across the full 
experiment (Figure 2-3b) shows shear rates extended from approximately  
–2500 to 15 000 s-1. The time-averaged mean wall shear rate for the pulsatile flow was 
calculated to be 3800 s-1. For comparison, the steady shear rates used were approximately 
16 000 s-1, 6500 s-1, and 3800 s-1, which fall within the maximum shear envelope measured 
for the pulsatile flow condition (Bark et al., 2012; Jackson, 2007). Note that the initial shear 
rates were set for all the experiments but that the subsequent shear rates vary as the 
thrombus occludes the lumen and the flow rate falls for both the pulsatile and steady flow 
conditions.  
 To assess the relevance of the experimental shear rates, the wall shear rates in a 
coronary artery were calculated assuming a normal physiological (mean) flow rate of  
2.2 mL/min (Ku, 1997) for a Reynolds number of 530 and a Womersley number of 2.2. 
Using Poiseuille flow assumptions, the mean wall shear rate in a 60% coronary stenosis is 
approximately 5500 s-1 and the shear rate ranges from -1700 to 10 000 s-1. The wall shear 
rate envelope obtained using the present experiment corresponds well to approximated 






Figure 2-3: Sample experimental shear rate waveform, (a) 10-second detail of shear 
waveform, filtered using low-pass equiripple filter with bandpass of 3 Hz and bandstop of 
5 Hz (Matlab, R2012a; The Mathworks, Inc.; Natick, MA), (b) shear waveform for full 
experiment time, unfiltered 
 
  
2.3.2 Thrombus Formation under Steady and Pulsatile Flow Conditions 
Figure 2-4 illustrates thrombus formation under pulsatile and steady conditions. Thrombus 
formation is seen as a brightening caused by the greater transmittance of platelet thrombus 
compared to whole blood. At tlag (Figure 2-4, first column), thrombus formation is observed 
as a slight roughness at the edge of the test section. By t = 0.75tocc (third column), thrombus 
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has progressed well into the test section, and at occlusion (last column), thrombus appears 
as a blockage at the throat of the stenosis. A qualitative comparison of these images does 
not reveal substantial differences in thrombus formation characteristics between the four 
conditions. The average pixel size is 7.5 μm/pixel, and we estimate an uncertainty of  
±1 pixel, or ±7.5 μm, in the identification of both the inner and outer edges of the thrombus. 
Propagating the uncertainty of ±7.5 μm through the subtraction of the two inner and two 
outer edges to the calculation of Di and Do gives an uncertainty of ±15 μm in the diameters. 
Propagating an uncertainty of ± 7.5 μm through the volume calculation in eq. (2-3) gives 




Figure 2-4: Time lapse transmitted intensity images of thrombus formation at lag time, 
50% of occlusion time, 75% of occlusion time, and occlusion time; top: pulsatile flow, 





 Characteristic thrombus formation and flow cessation are shown in Figure 2-5. 
Thrombus volume, V, versus t is shown in Figure 2-5a, along with linear fits from tlag to 
tocc. Figure 2-5b shows Di at the throat of the stenosis versus t for each of the experimental 
conditions, illustrating the closure of the throat of the stenosis. Figure 2-5b shows the 
discharge mass for steady flow conditions and the decrease in reservoir volume for the 
pulsatile case, illustrating the cessation of flow in the experimental apparatus. Figure 2-6 
and Table 2-1 compare thrombus formation characteristics of occlusion time, lag time, and 
growth rate (tocc, tlag, and dV/dt) under pulsatile and steady flow conditions. No statistical 
difference was observed for any metric between pulsatile flow and steady flow at mean 
pulsatile shear rate (p ≈ 0.29-0.69). However, high shear associated with the maximum of 
pulsatility was different. The lag time for first appearance of thrombus, tlag is significantly 
shorter for maximum steady shear compared to pulsatile shear (p = 0.03, unpaired t-test). 
tlag decreases from 42 ± 10 s to 26 ± 9 s (35% and 37%) for maximum shear versus pulsatile 
conditions. A similar decrease in tlag was seen between maximum steady shear and both 
mean shear (p = 0.01, unpaired t-test) and intermediate shear conditions (p = 0.02, paired 
t-test) (Figure 2-6b). In contrast, tocc for all steady conditions were within about 1 minute 
(17%) of that for pulsatile flow. Similarly, mean dV/dt also varied between conditions by 
approximately 25%. Most importantly, no endpoint differed between pulsatile to steady, 
mean shear conditions by more than 25%, and no endpoint showed statistically significant 







Figure 2-5: Characteristic thrombus formation and flow cessation. a) Thrombus volume 
versus time. Solid lines show computed thrombus volume, dotted lines show the slope of 
linear fits used to compute thrombus growth rate (dV/dt), and dashed line shows threshold 
volume for measurement of lag time (tlag). Linear fits have been translated for clarity. 
Thrombus volume was processed at 5 Hz and is plotted as a moving average with a period 
of 1 s. b) Lumen diameter at the throat of the stenosis versus time; c) Mass discharge 






Figure 2-6: Effect of flow pulsatility and shear rate on a) occlusion time, b) lag time, and 
c) thrombus growth rate, * indicates p < 0.05 compared to steady, maximum shear rate 
condition,  unpaired t-test, n = 5, and ** indicated p < 0.05, paired t-test, n = 5 
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5.5 ± 2.8 - 42 ± 9 - 5.0 ± 3.4 - 
Steady 




6.2 ± 1.7 0.63 61 ± 26 0.29 3.9 ± 2.2 0.49 
Steady 




4.6 ± 2.7 0.64 40 ± 11 0.66 5.7 ± 2.7 0.23 
Steady 




4.6 ± 1.75 0.57 26 ± 10 0.03 6.1 ± 1.9 0.35 
Values are given as mean ± standard deviation, p-values were calculated using an unpaired t-test 
(n = 4-5). 
 
 
2.4  Discussion 
Thrombosis leading to myocardial infarction and stroke forms under high shear rates and 
pulsatile flow conditions. In the present study, we show that in vitro thrombus formation 
under high shear pulsatile flow can be modeled using steady flow for the bulk thrombosis 
characteristics of lag time, occlusion time, and thrombus formation rate. We observed no 
difference in platelet thrombus formation between steady and pulsatile flow with the same 
mean shear rate, as did van Breugel et al. (van Breugel et al., 1988) for lower shear rates. 
Our study demonstrates the similarities for higher shear rates and pulsatile waveforms that 
include both flow reversal and non-zero mean shear. Our endpoints highlighting bulk 
thrombus formation reflect clinical occlusive thrombosis leading to myocardial infarction, 
rather than cellular level adhesion. 
 Our results are contrary to those of Zhao et al. (Zhao et al., 2008), who showed 
increased platelet deposition with pulsatile flow. Zhao et al. used a pulsatile period of  
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30 s (0.033 Hz) while the present study used a period of 1 s (1 Hz). Furthermore, the Zhao 
study employed lower shear rates (300 to 1300 s-1) and investigated surface coverage 
involving on the order of thousands of platelets and not occlusive thrombus formation 
involving millions of platelets. The combination of lower periods, non-pathologic low 
shear rates, and quantification of surface coverage rather than occlusion may explain the 
difference of our findings. Ultimately, the endpoint used by Zhao et al. may preclude the 
observation of rapid platelet accumulation described here, since their previous experiments 
were less than half the time of ours (Bark et al., 2012; Para et al., 2011). Alternatively, slow 
pulsatility may more strongly affect platelet surface coverage at low shears with adhesion 
time scales that may be on the order of 30 sec.   
 Flow pulsatility is unlikely to affect the binding of individual platelets since the 
platelet binding timescale of microseconds is short compared to an arterial pulsatile period 
of 1 sec (Wellings & Ku, 2012). Though flow conditions and the presence of red blood 
cells have been shown to enhance platelet transport to the vessel wall (Aarts et al., 1988; 
Eckstein, Tilles, & Milero, 1988),  a previous study showed no change near-wall platelet 
concentration as a result of pulsatility (Xu & Wootton, 2004). The present study also 
supports the results that pulsatility does not have a strong effect on factors like platelet 
margination that might affect lag time or thrombus growth rate for a matched mean shear 
rate. 
 We report a decrease in lag time with increasing mean shear rate from 3800 s-1 to 
16 000 s-1 but no difference in lag time when pulsatility is introduced at the same mean 
shear rate. Platelet activation time has previously been shown to be inversely proportional 
to shear rate (Hellums, 1994), which agrees with our observation of a decreased lag time 
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with increased shear rate. Previous studies have suggested that the lag time phenomenon 
may be related to the time required for shear activation of an initial layer of collagen-
adherent platelets (Bark et al., 2012; Para et al., 2011). The transit time of platelets through 
the stenosis is on the order of milliseconds, which is likely too short for shear activation 
prior to adhesion. Ramstack et al. (Ramstack, Zuckerman, & Mockros, 1979) found that 
shear activation of platelets occurred when the product of shear rate and exposure time 
exceeded threshold of 103. In the present study, exposure times range from 2.31 to 9.72 ms 
for shear rates from 16 000 s-1 to 3800 s-1. For all experimental conditions, the product of 
shear rate and transit time is only 37, several orders of magnitude less than the threshold 
for shear activation before platelet adhesion. Thus, evidence suggests non-activated 
platelets initially adhere to the collagen surface (Ruggeri, Orje, Haberman, Federici, & 
Reininger, 2006) and are subsequently activated by a combination collagen binding and 
shear, allowing large scale accumulation of thrombus. At the shear rates studied here, a 
combination of collagen-induced and shear-induced activation may contribute to platelet 
activation (Holme et al., 1997). The present study is unable to elucidate the relative 
contributions of collagen binding and shear to platelet activation, nor were alternative 
surface functionalization investigated. Rather our results describe the bulk effects of 
surface and flow conditions that are relevant in arterial thrombosis at the site of 
atherosclerotic plaque rupture.  
 The equal lag times between pulsatile and steady flow with matched mean shear 
rates further suggests that the product of shear rate and time (?̇? × t) (Ramstack et al., 1979), 
rather than maximum shear rate, may be an important determining factor for lag time. The 
brief excursions to very high shear rates under pulsatile are balanced by phases of lower 
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shear rate. Thus pulsatile flow imparts a shear history similar to steady flow at a matched 
mean shear rate, resulting in similar lag times, whereas steady maximum shear flow results 
in a decrease in lag time.   
 An alternative or complementary explanation of the decrease lag time with shear 
rate is an increased rate of plasma protein adsorption, in particular von Willebrand factor 
(vWF). At high shear rate, vWF is the principle mediator of platelet-collagen bonding 
(Ruggeri, 2007). High shear rate enhances the diffusion of solutes (Taylor, 1953) and 
particles in suspension (Leighton & Acrivos, 1987). Thus increasing shear rate increases 
the diffusivity of vWF and platelets in flowing blood, allowing faster adsorption to the 
collagen substrate and decreasing lag time (Neeves et al., 2013). 
 The effects of enhanced shear activation on occlusion time and overall thrombus 
growth rate at the maximum shear rate may be balanced by increased embolization due to 
higher drag forces at higher shear rates, yielding minimal differences in growth rate and 
occlusion time over the duration of the experiment. Furthermore, after initial activation, 
thrombus growth may no longer be limited by protein transport and absorption as activation 
of platelets at the surface releases large concentrations of vWF and other factors locally 
(Ruggeri et al., 2006; Wellings & Ku, 2012). However, the rate-limiting mechanisms of 
the growth phase remain an unanswered question to be investigated by future studies. 
 The present study has several limitations. First, only a single pulsatile waveform 
was analyzed in the present study. The waveform was selected to mimic flow and shear 
rates within a stenotic coronary artery under resting conditions, including flow reversal and 
non-zero mean shear rate. Though a relevant physiological waveform was selected, we did 
not investigate variations in pulse frequency and amplitude. Had the pulsatility created a 
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significant effect, we would have characterized a frequency response curve. But, since the 
base frequency did not have a measurable effect, it is unlikely that higher frequency terms 
will have much effect, either. Our pulse amplitude going from 0 to 16 000 s-1 likely exceeds 
most arterial waveform conditions, so may be considered a worse-case. The experimental 
apparatus employed rigid walls and thus did not include contributions of arterial wall 
elasticity to thrombus formation. To routinely obtain blood volumes large enough for the 
single-pass flow system, porcine rather than human blood was used. Porcine blood has 
been shown to be similar to human platelet thrombosis in previous studies (Badimon et al., 
1986; Bark et al., 2012; Para et al., 2011). Some variations may exist between porcine and 
human thrombus formation, in particular, lag time is approximately twice as long with 
human blood compared to porcine blood and the rate of thrombus growth is approximately 
half as fast (Para & Ku, 2013). To prevent coagulation during transport, blood was lightly 
anticoagulated with heparin, which may inhibit the contribution of thrombin generation 
and fibrin formation to thrombus growth.  
 
2.5  Conclusions 
Pulsatile and steady flow experiments yielded similar results for the endpoints of thrombus 
growth rate, lag time and occlusion time when the steady time-averaged mean shear rate at 
the wall matched that of pulsatile shear rate. Steady shear rates equal to the maximum 
pulsatile shear, however, exhibited a decreased lag time. The results indicate that 
hemodynamic assays for platelet thrombosis may use the simpler steady flow arrangement 
with corresponding clinical relevance to pulsatile arterial conditions with good persistence 




2.6  Appendix 
2.6.1 Reynolds Number 
The Reynolds number (Re) is the non-dimensional ratio of inertial forces to viscous forces. 






Re  (A1) 
where ρ is the fluid density, L is the diameter of the test section, Umean is the mean velocity 
at the throat, and μ is the fluid viscosity. The density and viscosity of blood were taken as 
1050 kg/m3 and 3.24 × 10-3 Pa-s, respectively (Kenner, 1989; Merrill, 1969). Outside the 
stenosis, the diameter was 1.5 mm and the average velocity ranged from 0.0075 m/s to 
0.034 across the three steady flow conditions, yielding a Reynolds number between 3.6 
and 16.5. Inside the stenosis throat, an average diameter of 325 μm was used, and the 
average velocity ranged from 0.16 m/s to 0.687 m/s, yielding a Reynolds number between 
17 and 72. 
 
2.6.2 Schmidt Number 
The Schmidt number (Sc) is the non-dimensional ratio of momentum diffusivity to mass 




Sc  (A2) 
where d is the diffusivity of platelets. Platelet diffusivity may be considered either as the 
diffusivity of platelet in plasma, or as the effective diffusivity of platelets in blood under 
flow. Platelet diffusivity in plasma is 1 × 10-13 m2/s (Jordan, David, Homer-Vanniasinkam, 
Graham, & Walker, 2004). However, since blood is a dense suspension of cells, effective 
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platelet diffusivity increases with shear rate. Effective diffusivity (Deff) cab be estimated 
by (Jordan et al., 2004; Zydney & Colton, 1988) 
    15.02 18.0   add sfeff  (A3) 
where dsf  is platelet diffusion in plasma (1 × 10
-13 m2/s), a is the radius of the red blood 
cells (4.2 μm), γ is the shear rate, and φ is the hematocrit (0.4). Using this equation, the 
maximum platelet diffusivity using the wall shear rates is 8.3 × 10-8 m2/s. Substituting the 
values for diffusivity into eq. (A2) gives a maximum Sc at the throat of the stenosis for the 
no-shear condition of 3.7 × 106, and effective Sc between 154 for the mean shear condition 
and 37 for the maximum shear condition. This range of Sc reflects that platelet diffusion is 
slower than fluid momentum transfer. 
 
2.6.3 Peclet Number 
The Peclet number (Pe) is the non-dimensional ratio of advective transport rate to diffusive 
transport rate. Pe is defined as 
  ScRePe 
d
LUmean .  (A4) 
Multiplying the above values for Re and Sc for the various experimental conditions yields 
a Pe at the throat of the stenosis of between 6.2 × 107 and 2.6 × 108 for the minimum 
diffusivity, and between 2618 and 2664 using values for effective diffusivity. Such high 
Peclet numbers suggest that the platelet mass transport is dominated by the fluid flow and 
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CHAPTER 3: MICROFLUIDIC DEVICE DESIGN 
3.1  Design Requirements 
For the design of a useful, point-of-care high shear thrombosis assay, several design criteria 
were identified. Many of the design criteria relate directly to the test section size and shape. 
The four key requirements, summarized in Table 3-1 are low blood volume, physiological 
and pathological shear rates, practical total test times, and occlusion dominated by platelet-
platelet interactions relevant to large artery occlusive thrombus. The design of each of these 
criteria is considered in the following sections. In addition to these requirements, several 
human factors criteria will be targeted, namely, fully disposable test cassettes, the ability 
to perform multiple tests, and straight-forward endpoints obtained by non-additive, non-
contact measurement techniques. 
 
Table 3-1: Test Section Design Criteria 
Design Criteria Design Target 
Total Blood Volume < 10 mL 
Shear Rate (in stenosis) ~6000 s-1 
Shear Rate (outside stenosis) ~500 s-1 
Test time 5-30 min 






3.2  Geometric Design of Microfluidic Chambers: Platelet Adhesion versus 
Accumulation 
3.2.1 Introduction 
Platelet thrombosis related to myocardial infarction and stroke forms under arterial flow 
conditions (Cadroy, Horbett, & Hanson, 1989) and is initiated by platelet interactions with 
extracellular matrix proteins such as collagen or fibrinogen (Savage, Saldivar, & Ruggeri, 
1996; Savage, Almus-Jacobs, & Ruggeri, 1998) exposed by atherosclerotic plaque rupture 
(Falk, 1983). Subsequently platelet-platelet adhesion creates the large volume of thrombus 
growth (Maxwell et al., 2007) leading to occlusion of flow in atherosclerotic arteries 
(Davies & Thomas, 1984). Intravascular thrombosis of medium and large arteries is 
dominated by platelet-platelet interactions due to the large ratio of thrombus volume-to-
surface area in the occluded region.  
 Microfluidic systems are designed to utilize small fluid volumes. However, the 
quest for miniaturization may skew the study towards platelet-surface adhesion due to the 
larger surface area relative to thrombus volume. Platelets adhere to extracellular matrix 
proteins via different molecular mechanisms than platelet-platelet binding (Ruggeri & 
Mendolicchio, 2007). Thus, test channels that are very small may create platelet surface 
adhesion, while larger ones can test for platelet-platelet bonding. The question is “How 
small is small?” To quantify the type of platelet adhesion event within a test channel, we 
characterize microfluidic assays as dominated by either platelet-surface or platelet-platelet 
interactions. Multiple investigators have described flow assays to quantify platelet 
adhesion, summarized in Table 3-2. Some of the studies utilized surface coverage 
measurement techniques and short test times to isolate platelet-surface interactions. Others 
created a thrombus that fills a large portion or all of the test section, and it is unclear 
62 
 
whether platelet-platelet or platelet-surface effects were dominant. Though the results of 
these studies depend on many factors including time, shear rate, and biomolecular 
interactions, the dominant type of platelet adhesion event, namely platelet-surface or 
platelet-platelet, depends on size of the test section and final thrombus volume. In future 
studies, it may be advantageous to design test sections to separate the effects of the different 
platelet adhesion mechanisms. In particular, it is of interest to determine the minimum 
allowable size of a microfluidic test section that still permits the observation of large-scale 
occlusive thrombosis in which many more platelets adhere to each other rather than to the 
test section walls. 
 
Table 3-2: Summary of Previous Arterial Platelet Adhesion and Aggregation Assays  
Test Section 
Geometry 
Test Time Endpoint References 
Cylindrical (stenosed) 




(Badimon, Badimon, Galvez, 
Chesebro, & Fuster, 1986; 
Badimon & Badimon, 1989; 
Mailhac et al., 1994) 
 D = 1.3 mm 
 D = 0.9 mm 
  D = 4 mm 
 
D = 300 um 20 min. 
Thrombus 
volume 
(Bark, Para, & Ku, 2012; Ku & 
Flannery, 2007; Para, Bark, Lin, 
& Ku, 2011) 
Parallel Plate 
  
h = 1 mm,  
w = 10 mm 




(Houdijk, de Groot, Nievelstein, 
Sakariassen, & Sixma, 1986; 




h = 254 m,  
w = 0.22 cm 





(Savage et al., 1996; Savage et 
al., 1998; Savage, Ginsberg, & 
Ruggeri, 1999; Usami, Chen, 
Zhao, Chien, & Skalak, 1993) 
  
h = 0.1 mm,  
w = 5 mm 




(Sixma, de Groot, van Zanten, & 
Ijsseldijk, 1998) 
  
h = 60 m,  
w = 250 m 




(Colace, Muthard, & Diamond, 




Table 3-2: Summary of Previous Arterial Platelet Adhesion and Aggregation Assays  
Test Section 
Geometry 
Test Time Endpoint References 
  
h = 80 m,  
w = 100 m 




(Neeves et al., 2008) 
  
h = 24 m,  
w = 200 m 
 = 8.3 
1 min. Fluorescence (Gutierrez et al., 2008) 
  
h = 80 m,  
w = 300 m 
 = 3.75 
30 min. 
(occlusion) 
Pressure drop (Hosokawa et al., 2011) 
  
h = w = 40 m 
 = 1 
10 min 
(occlusion) 
Pressure drop (Hosokawa et al., 2012) 
Parallel Plate (stenosed) 




(Barstad, Roald, Cui, Turitto, & 
Sakariassen, 1994; Barstad, 
Hamers, Stephens, & 
Sakariassen, 1995; Barstad, 
Roald, et al., 1995; Bossavy, 
Sakariassen, Thalamas, Boneu, 
& Cadroy, 1999; Sakariassen et 
al., 1990) 
 
h = 0.7 mm,  
    = 7.1 
 
h = 0.28 mm,  
    = 17.9 
 
h = 0.14 mm,  
    = 35.7 
  
h = 0.08 mm,  
    = 62.5 
  
h = 250 m,  
w = 750 m 






(Li, Ku, & Forest, 2012) 
 
 
The objective of the present study is to determine the dimensions and conditions 
for microfluidic assays that favor one type of platelet interaction over another. The ratio of 
platelet-platelet to platelet-surface interactions, R, and the percent of platelet-platelet 
interactions, P, are estimated for circular and rectangular test section geometries. For 
rectangular test sections, a range of channel aspect ratios were considered: channels with 
all sides functionalized versus only one side functionalized, where “functionalized” refers 
to areas of the channel coated with an adhesive protein. The effects of platelet size and 
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shape were also investigated, and analytical predictions are shown experimentally by 
comparing a rectangular microfluidic channel to a circular test section that mimics a 
stenotic coronary artery. Results of this analysis may be useful for the development of 
micro-scale assays to study either cell-cell or cell-surface bonding. Results may also be 
extended to characterize micro- and nano-fluidic analyses of leukocyte accumulation, 
three-dimensional cell culture, and colloidal fouling. 
 
3.2.2 Methods 
3.2.2.1 General Analysis 
In general, the ratio, R, of platelet-platelet to platelet-surface interactions and the 











P   (3-2) 
where Ntot is the total number of adhered platelets, and Ns and Np are the number of platelets 
adhered to the surface and to other platelets, respectively. Since in many experimental 




N tot   (3-3) 
where V is the measured thrombus volume per unit length, p is the fraction of the thrombus 
composed of platelets, here assumed to be 80% (p = 0.8) (Ku & Flannery, 2007), and v is 
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the average volume of an individual platelet. The number of surface-adhered platelets, Ns, 




N s   (3-4) 
where A is the area of the functionalized surface supporting platelet adhesion per unit 
length and a is the area occupied by an individual adhered platelet. Finally, the number of 
platelets adhered to other platelets, Np, was calculated as 
  stotp NNN  .  (3-5) 
 
3.2.2.2 Analysis for Fully Occluded Test Sections 
The effect of channel dimensions on R and P were analyzed based on the following. Two 
common test section geometries, circular and rectangular (Figure 3-1), were considered in 
the present analysis. Circular cross-sections were quantified by diameter, D, and 
rectangular test sections were characterized by height, h, and aspect ratio, , defined as 
width over height, w/h. For circular test sections, the entire inner surface was considered 
functionalized to support platelet adhesion. For rectangular test sections, two surface 
functionalization configurations were considered. First, all interior surfaces were 
considered functionalized. The analysis was repeated assuming only one surface, either the 
top or bottom, was functionalized, similar to previous experiments (Barstad et al., 1994; 
1995; 1995; Bossavy et al., 1999; Colace, Jobson, & Diamond, 2011; Gutierrez et al., 2008; 
Hosokawa et al., 2011; 2012; Houdijk et al., 1986; Maloney et al., 2010; Neeves et al., 
2008; Sakariassen et al., 1983; Sakariassen et al., 1990; 1996; Savage et al., 1998; 1999; 
Sixma et al., 1998). For all geometries, the analysis was performed assuming a section of 





Figure 3-1: Test section geometry, (A) circular, (B) rectangular 
 
 
  For test sections that are fully occluded by thrombus, the thrombus volume per unit 
length for circular and rectangular test sections, VC and VR, respectively, were calculated 







 , (3-6)  
  
2hVR   (3-7) 
where  is the aspect ratio of the rectangular channel defined as width divided by height 
(w/h). For test sections with all surfaces functionalized to support platelet adhesion, the 
adhesive area per unit length for circular and rectangular test sections, AC and AR, 
respectively, were calculated from geometry as 
  DAC  , (3-8) 
  )1(2  hAR . (3-9) 
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Substituting eqs. (3-6) and (3-8) into eqs. (3-1) to (3-5) and simplifying gave the following 













1  (3-11) 
where p is the percentage of the thrombus composed of platelets, v is the volume of an 
individual platelets, and a is the surface area occupied by an individual platelet. Similarly, 



















  (3-13) 
 In many experimental assays (see Table 3-2),  a rectangular test section has been 
used with only the bottom or top surface functionalized to support platelet adhesion to 
simulate local atherosclerotic plaque rupture. In this case, the occlusive thrombus volume 
is identical to that given in eq. (3-7), but the area per unit length, AB was calculated as 
  hAB  . (3-14) 
Substituting again into eqs. (3-1) to (3-5) gave the following for occlusive thrombus in 










PB 1 . (3-16) 
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 For the present analysis, D was varied from 10 m to 1000 m for circular test 
sections, and for rectangular test sections, h was varied from 20 m to 1000 m and  from 
1 to 70. Dimensions were chosen to correspond with the range of test section dimensions 
summarized in Table 3-2 as well as to investigate smaller microfluidic test sections. 
Channel dimensions less than 10 m were not considered based on observations that 
average human platelet diameters are approximately 3.6 m (Frojmovic & Panjwani, 
1976), and thus very small dimensions would allow only one or two platelets to fill the 
cross-section. For the initial analysis, platelets were assumed spherical with v = 6.5 fL 
(Frojmovic & Panjwani, 1976). 
 
3.2.2.3 Analysis for Partially-Occluded Test Sections 
Many of the studies listed in Table 3-2 have short experiment times such that the 
rectangular test section was only partially occluded. In these cases, only one surface of the 
test section was functionalized, so eq. (3-14) is valid for the adhesive area per unit length. 
Either thrombus volume, VR,part, or thrombus thickness, m, was measured. In the case where 
m was measured, VR,part was calculated as  
  hmV partR , . (3-17) 
Substituting into eqs. (3-1) to (3-5) gave the following for partially occlusive thrombus in 
a rectangular channel. 
  1, 
v
map




P partR 1, . (3-19) 
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The partial occlusions mirrors the fully-occluded test sections with only the one surface 
functionalized, and are not treated separately in the Results section, but were used to 
analyze the previous results shown in Table 3-2. 
 Though not applicable to the studies shown in Table 3-2, for completeness, partially 
occlusive thrombus in a circular channel has an adhesive area per unit length given by  
eq. (3-8) and a volume per unit length, VC,part, given by 





Substituting into eqs. (3-1) to (3-5) gave the following for partially occlusive thrombus in 
a circular channel. 






R partC  (3-21) 







P partC  (3-22) 
 
3.2.2.4 Effect of Platelet Shape and Size 
Using the analysis above, the effect of platelet size and shape were also analyzed. For 













d . (3-23) 
The area occupied by a surface-adhered platelet was assumed to equal the maximum cross-
sectional area, namely a = d2/4.  
 Discoid platelets were also analyzed, oriented such that they adhered with their 
major axis parallel to the surface, “flat,” or with their major axis perpendicular to the 
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surface, “upright.” Discoid platelet volume and geometry were quantified based on 








  (3-24) 
where d is the diameter and t is the thickness of the platelet. An axis ratio of 0.3 was 
assumed (Frojmovic & Panjwani, 1976), so  t = 0.3d, and eq. (3-16) was solved for d with 
v = 6.5 fL. For platelets adhered in the flat position, a was assumed equal to the maximum 
cross sectional area, a = d2/4, and for platelets in the upright position, a was assumed 
equal to the rectangular projection of the platelet, a = td. The effect of platelet size was 
also analyzed by increasing v from 6.5 to 26 fL, four times the average platelet volume and 
at the upper range of observed platelet volumes (Paulus, 1975). Figure 3-2 illustrates the 




Figure 3-2: Platelet and adhesion geometry. For the initial analysis, all platelets were 
assumed to have the same volume of 6.5 fL. For spherical platelet (left), the diameter, d, 





3.2.2.5  Particle Size Distribution 
In vivo, platelet size varies according to a lognormal distribution with a log-mean of   
1.68 fL and a log-standard deviation of 0.61 fL (Paulus, 1975). To model the effect of 
platelet volume variation, repeated Monte Carlo simulations of platelet adhesion were 
performed by generating arrays of random platelet sizes according to this distribution. The 
array represented sequentially bound platelets within the test sections. Stepping through 
the array, the functionalized surface of the test section was assumed to be coated first by 
subtracting the calculated area of the platelet from the total functionalized surface area and 
the volume of the platelet from the total test volume. After full surface coverage, each 
subsequent adherent platelet volume was subtracted from the total test volume until it was 
completely filled. The algorithm assigned first all surface-bound and then all platelet-
bound platelets. This assignment may not necessarily mimic in vivo or in vitro thrombosis, 
but rather was employed as a way to systematically step through the array of platelet sizes. 
Assigning platelet locations randomly within the test volume and then analyzing the 
surface- versus platelet-bound platelets does not affect the results. R and P were calculated 
for each simulation based on the number of platelets adhered to the surface and total 
number of platelets necessary to fill the test section volume. The simulations were repeated 
at least 4 times and continued until the standard error of the mean (standard deviation 
divided by the square root of the number of trials) was less than 1% of the mean for both 




3.2.2.6 Experimental Demonstration of R > 10 
To illustrate the applicability of the preceding analysis to experimental systems, a 
rectangular microfluidic stenotic test section was designed with R > 10 yielding cross-
sectional dimensions of h = 70 m and w = 475 m ( = 6.8). The test section was 
fabricated from PDMS and plasma-bonded to a glass microscope slide using standard 
techniques. To support platelet adhesion, the test section was coated with fibrillar collagen 
Type I (Chronopar; Chronolog, Inc.; Havertown, PA) for 24 hours in a warm, moist 
environment and rinsed with PBS prior to experimentation. Whole blood was obtained 
from a healthy donor under an approved IRB protocol. Blood was lightly heparinized at 
3.5 USP units/mL (Para et al., 2011). Blood was perfused through the test section as a mean 
shear rate of 6500 s-1 under a constant pressure head.  
 To compare microfluidic test section performance to a test section that more closely 
mimics coronary artery geometry, whole blood from the same donor was also perfused 
through a circular stenotic  glass test section (R > 10, D  = 345 m, 77% stenosis), as 
described previously (Ku & Flannery, 2007; Para et al., 2011). The test section was 
incubated with collagen, and the mean shear rate was matched to that of the microfluidic 
system. In the circular system, the discharge mass was measured using a scale.  
 Microscopy images of thrombus formation in each test section were recorded at  
2 Hz using a high resolution CCD (Pixelfly; PCO; Kelheim, Germany) attached to a stereo 
microscope (Leica DM5000b; Leica Microsystems; Wetzlar, Germany and Stemi 2000-C; 
Carl Zeiss; Oberkochen, Germany). The images were analyzed using an automated image 
analysis program developed in MATLAB (R2012a; The Mathworks, Inc.; Natick, MA). 
For both systems, a reference image taken prior to thrombus formation was selected and 
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subtracted from subsequent images to highlight intensity changes resulting from the 
thrombus. For the microfluidic system, the total intensity in the region of interest was 
quantified as a surrogate for thrombus volume, which is not readily obtainable from the en 
face images. In the circular system, thrombus was identified using a user-defined threshold, 
and the thrombus volume was then estimated using a summation of differential volumes 
(Para et al., 2011).  
 Platelet adhesion to the collagen surface is characterized by a lag time before large 
thrombus formation. In contrast, platelet-platelet volume growth is characterized primarily 
by the occlusion time. The lag time, tlag, and the occlusion time, tocc, were quantified for 
both test sections. For the microfluidic system, tlag was identified from the intensity versus 
time graph as initial non-linear region of thrombus formation, and tocc was determined by 
identifying the microscopy image in which flow ceased, based on cell motion. For the 
circular, true-sized system, tlag was defined as when the thrombus volume in the region of 




3.2.3.1 Analytical Results  
In circular test sections, RC increased linearly with D (Figure 3-3a), and PC asymptotically 
approached 100% (Figure 3-3b). Similar results were seen for rectangular test sections 
(Figure 3-4). As  decreased in rectangular channels, the rate of increase of both RR and 
PR decreased, and thus low aspect ratio channels favor platelet-surface interactions. For 
rectangular channels with only one surface supporting platelet adhesion,  does not affect 
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RB or PB (Figure 3-5) as evident by the absence of  in eqs. (3-15) and (3-16). Rectangular 
sections with only one surface functionalized had higher R and P and thus favor platelet-




Figure 3-3: Effect of circular test section size on (A) platelet-platelet to platelet-surface 







Figure 3-4: Effect of rectangular test section size with all sides functionalized on (A) 






Figure 3-5: Effect of rectangular test section size with single surface functionalization on 




 Defining R ≥ 10 (that is, ten times as many platelet-platelet adhesion events at 
platelet-surface adhesion events) as a threshold for an assay dominated by platelet-platelet 
interactions, circular test sections meant for full occlusion during experimentation should 
be manufactured with D ≥ 90 m. Rectangular sections with low aspect ratios and all 
surfaces functionalized should have h ≥ 90 m. Rectangular sections with large aspect 
ratios may be reduced to h > 50 m and still be dominated by platelet-platelet interactions. 
 In rectangular channels with only one surface functionalized, h should be greater 
than 20 m for platelet-platelet interactions to dominate thrombus formation. To isolate 
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platelet-surface interactions (P < 50%), circular channels with D < 20 m should be used. 
Alternatively, rectangular channels with only the one surface functionalized may be used 
to isolated platelet-surface interactions provided that thrombus thickness is limited to less 
than 10 m.  
 Discoid platelets can be oriented flat to the surface or with their major axis 
perpendicular to the surface (upright). Figure 3-6 shows the effect of platelet shape on R 
and P in circular channels. Similar results were obtained for rectangular channels, but are 
not shown for conciseness. The effect of changing platelet shape from spherical to discoid 
had a limited effect on R and P when platelets are oriented flat against the test section wall 
(Figure 3-6), with discoid platelets slightly increasing R and P compared to spherical 
platelets. When platelets are oriented upright against the wall, R is substantially decreased 
compared to spherical platelets, and P is substantially decreased at small D with less effect 
as D increases. The larger effect of upright platelets compared to spherical platelets is due 
to an increase in the ratio of platelet volume to occupied surface area, v/a, from 1.4 m for 
spherical platelets to 2.9 m for upright platelets. Each surface adherent platelet occupies 
more volume per unit area in the upright position than in the flat or spherical position. This 
increases the number of platelets necessary to cover the surface without affecting the total 
number of platelets in the volume, thus resulting in a larger decrease in both R and P. In 
the case of flat platelets, v/a is slightly decreased compared to spherical platelets to 1.1 m, 
resulting a smaller opposite effect. Given that Maxwell et al. (2006) showed that platelet 
morphology during translocation varies between discs adhered flat against the wall and 
spheres depending on shear rate, the case of upright platelet adhesion seems unlikely under 
high shear. Thus, the results of platelet shape variation suggest that a simplified spherical 
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geometric assumption yields similar results to flat platelet adhesion and is likely sufficient 
for design and characterization of microfluidic platelet assays. 
 
 
Figure 3-6: Effect of platelet shape on (A) platelet-platelet to platelet-surface interaction 
ratio, RC, and (B) percent platelet-platelet interactions, PC, in circular test sections 
 
 
 Based on the preceding results classifying test section dimensions of <20 m for 
predominately platelet-surface interactions, or >90 m for predominately platelet-platelet 
interactions, the subsequent analyses were performed for test sections sizes of 20, 100, and 
500 m ( = 10 for rectangular channels). Increasing platelet volume, v, from 6.5 to 26 fL 
had a large effect on R for all platelet shapes and test section geometries (Figure 3-7), with 
R decreasing 37-174% depending on the test section geometry and platelet shape. The 
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percent decrease was greatest in circular channels with D = 20 m and for platelets in the 
upright orientation. In rectangular channels, R decreased by 37.1% to 43.6% when discoid 
platelet volume was increased from 6.5 fL to 26 fL. 
 
 
Figure 3-7: Effect of platelet volume on platelet-platelet to platelet-surface interaction 
ratio, R (left column), and percent platelet-platelet interactions, P (right column) for (A) 
circular channels and rectangular channels,  = 10, with (B) all surfaces functionalized and 





 Monte Carlo simulations were performed for spherical platelets in each test section 
geometry with D or h = 20, 100, and 500 m and  = 10. The results of the Monte Carlo 
simulation are compared with the deterministic results in Table 3-3. Results for R differed 
by less 10% from the deterministic results, and P by less than 1% except in the smallest 
test sections analyzed. Platelet variability had a greater effect in small test sections because 
individual platelets with smaller- or larger-than-average volumes result in a greater percent 
difference in the area and volume occupied compared to the test section dimensions, 
yielding larger differences in R and P. Still, the small effect of platelet variability on R and 
P suggests that the deterministic equations derived are likely sufficient for most test section 
characterization and design. 
 
Table 3-3: Summary of Monte Carlo Simulation Results 
Ratio (R) 
  
Circular Test Sections 





























20 1.6 1.47 -8.26% 3.7 3.54 -4.74% 9.4 8.85 -5.80% 
100 12.0 11.34 -5.45% 22.6 21.68 -4.06% 50.8 48.68 -4.42% 
500 63.8 61.77 -3.26% 116.8 112.00 -4.27% 258.1 249.20 -3.58% 
          
Percentage (P) 
  
Circular Test Sections 





























20 61.4% 59.2% -3.82% 78.8% 78.0% -1.06% 90.4% 89.8% -0.58% 
100 92.3% 91.9% -0.44% 95.8% 95.6% -0.17% 98.1% 98.0% -0.09% 





3.2.3.2 Experimental Results 
We studied the effect of R and P on observed thrombosis in two test section. Based on the 
geometric analysis, the circular, true-size test section yielded values of R = 43.7 and  
P = 97.8%. Assuming all surfaces of the rectangular microfluidic test section absorbed 
collagen, the lower bounds of R and P were R = 14.8 and P = 93.7%. However, studies 
have suggested that collagen is absorbed more readily onto glass than PDMS (Li, 2013). 
Assuming only the bottom glass surface of the channels was coated with collagen, we 
calculate R = 35.3 and P = 97.2% for our rectangular microfluidic experiments. In both 
cases, the test sections had the R ≥ 10 required to observe predominantly platelet-platelet 
adhesion events and should be comparable. 
 Thrombus formation in each test section is shown in Figure 3-8. In the circular, 
true-sized test section, thrombus formation can be seen as a narrowing of the lumen. 
However, in the microfluidic system, en face imaging through the flowing blood shows 
thrombus as progressively brighter regions. Total intensity in the microfluidic test section 
and thrombus volume in the true-sized test section are illustrated in Figure 3-9. Curves for 
each metric appear qualitatively similar, each with a clear initial region of minimal 
thrombus formation, a region of rapid, nearly linear increase in thrombus, a region of 
minimal thrombus growth near tocc, and a sharp increase in intensity after occlusion. This 
final region of intensity build-up after occlusion may be due to thrombus compaction, 
which increased the image intensity and results in increased thrombus detection. For both 
test sections, tlag were similar (Figure 3-9a) at 113 s in the microfluidic system and 133 s 
in the true-sized system, a difference of only 15%. Lag time is thought to occur from the 
absorption of plasma proteins, such as von Willebrand factor, that support high-shear 
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platelet adhesion and may also account for initial activation of surface-bound platelets. Lag 
time may be somewhat shorter in the microfluidic system due to the small surface area onto 
which proteins and platelet initially adhere. To compare the later stages of thrombus 
formation, the time after tlag, Δt, was normalized by tocc to account for difference in test 
section volume that must be fill with thrombus (Figure 3-9b). Under this normalization, 
the similarities in thrombus formation between the two test sections are striking. The 
similarities support our analysis that large-scale platelet accumulation can be created in 
two test sections with very different geometry and size as long as the ratio R is above 10.  
 
 
Figure 3-8: Experimental test sections, (a) and (b) non-thrombosed and occluded 
rectangular, microfluidic test section, (c) and (d) non-thrombosed and occluded circular, 






Figure 3-9: Intensity in 70 µm rectangular test section (black) and thrombus volume in 
true-sized circular test section (gray) versus (A) perfusion time and (B) non-dimensional 




Platelet thrombosis leading to arterial occlusion proceeds by platelet-surface interactions 
followed by platelet-platelet interactions, which are modulated by different adhesion 
receptors. To create these interactions in vitro, test section size is important. Based on the 
present analysis, the geometric dimensions of microfluidic assays can be used to create 
situations that are dominated by either type of interaction. The dominant interaction type 
was quantified by the ratio, R, of platelet-platelet to platelet-surface interactions and the 
percentage, P, of platelet-platelet interactions to total number of platelets. Analysis of 
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platelet shape showed that the spheres may be used as a reasonable approximation for 
discoid platelets. Platelet size also affects adhesion, but physiologic distributions of platelet 
populations do not result in large errors. 
 Test sections with circular geometry should be designed with D ≥ 90 m to create 
an assay dominated by platelet-platelet interactions (R > 10). For rectangular test sections, 
large aspect ratio channels with h ≥ 50 m or low aspect ratio channels with h ≥ 90 m 
should be used for predominately platelet-platelet interactions. Specifically, the 
applicability of a sufficiently large (R > 10) microfluidic test section for the study of 
occlusive arterial thrombosis in a coronary-sized vessel was demonstrated. Furthermore, 
experimental results may be extrapolated to conclude that in smaller test sections, thrombus 
formation would not progress past the lag time portion of the curve, and the distinct modes 
of large-scale, occlusive thrombus formation, particularly rapid platelet accumulation, 
would not be observed.  
 For predominately platelet-surface interactions (P < 50%), a circular test section 
should be designed with D ≤ 20 m. For experiments that do not proceed to full occlusion, 
a rectangular test section with only the one surface functionalized may yield predominately 
platelet-surface interactions provided that the analysis is limited such that the thrombus 
thickness is less than 10 m. 
 Table 3-4 lists the results of the present analysis applied to test section geometries 
from previous studies. In all experiments of this type, the dominant type of platelet 
interaction is determined by three factors: 1) test section geometry, 2) final thrombus 
volume determined either by occlusion or experimental time, and 3) the type of 
measurement endpoint. Several studies (Houdijk et al., 1986; Neeves et al., 2008; 
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Sakariassen et al., 1983; Sixma et al., 1998), address platelet-surface adhesion by 
measurement of surface coverage only as the experimental measurement endpoint. The 
results of the study by Gutierrez et al. (2008) were not conducive to the present analysis, 
and the study was classified as a platelet-surface study due to the short test time of one 
minute. For these studies, R and P were calculated for thrombosis of the full test section 
volume. In all cases, the use of additional measurement endpoints combined with 
sufficiently long test times for large thrombus volumes would allow these test sections to 
be used for platelet-platelet interaction studies as well as platelet-surface interaction. For 
the remaining studies listed, either thrombus volume or full test section occlusion was 
measured, and the present analysis was applied to distinguish between studies measuring 
platelet-surface and platelet-platelet interactions. Except in the study by  
Savage et al. (1998), these studies had R >> 10 and P > 95%, indicating that the results of 
these experiments are dominated by platelet-platelet interactions and not platelet-surface 
interactions. In Savage et al. (1998) thrombus volume was constrained by short 




Table 3-4: Application of Analysis to Previous High Shear Platelet Adhesion and 
Aggregation Assays 








Cylindrical (stenosed)  





(Badimon et al., 
1986; Badimon 
& Badimon, 
1989; Mailhac et 
al., 1994) 
 D = 1.3 mm 213.4 99.5% 
 D = 0.9 mm 78.2 98.7% 
  
D = 4 mm 73.8 98.7% 
 





(Bark et al., 
2012; Ku & 
Flannery, 2007; 
Para et al., 2011) 
Parallel Plate  
  
h = 1 mm,  
w = 10 mm 











h = 254 m,  
w = 0.22 cm 






(Savage et al., 
1996; 1998; 
1999; Usami et 
al., 1993) 
 0.4 0.02% 
  -0.3 -0.03% 
  
h = 0.1 mm,  
w = 5 mm 






(Sixma et al., 
1998) 
  
h = 60 m,  
w = 250 m 






(Colace et al., 
2012; Maloney 
et al., 2010) 
  
h = 80 m,  
w = 100 m 






(Neeves et al., 
2008) 
  
h = 24 m,  
w = 200 m 






(Gutierrez et al., 
2008) 
  
h = 80 m,  
w = 300 m 









h = w = 40 m 
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Table 3-4: Application of Analysis to Previous High Shear Platelet Adhesion and 
Aggregation Assays 








Parallel Plate (stenosed) 





(Barstad et al., 
1994; 1995; 





h = 0.7 mm,  
 = 7.1 
394.9 99.8% 
 
h = 0.28 mm,  
 = 17.9 
157.4 99.4% 
 
h = 0.14 mm,  
 = 35.7 
78.2 98.7% 
  
h = 0.08 mm,  
 = 62.5 
44.2 97.8% 
  
h = 250 m,  
w = 750 m 






(Li et al., 2012) 
 
† - For studies that measured surface coverage, and therefore only platelet-surface 
interactions, the maximum possible R and P for the given geometry were calculated 
 
 
 In occlusive thrombus formation, which can lead to heart attack and stroke, many 
more platelet-platelet interactions occur compared to platelet-surface interactions, and thus 
it would be advantageous to design a test section dominated by platelet-platelet interactions 
while minimizing the flow rate required for pathological shear rates. The present analysis 
yields the minimum test section dimensions that result in more platelet-platelet 
interactions, providing an optimum test section size for both reducing blood volume and 
ensuring the observation of relevant adhesion events. For clinical application of high shear 
platelet testing, it is necessary to reduce the required blood volume to less than 10 mL, 
amounts obtainable by routine phlebotomy.  
 The present analysis may also be applied to the adhesion and accumulation of other 
cells in microfluidic assays. For example, leukocyte accumulation may occur 
simultaneously with platelet aggregation (Hu et al., 2003; Khreiss, Jozsef, Potempa, & 
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Filep, 2004), or in response to platelet microparticle release (Forlow, McEver, & Nollert, 
2000) or ischemic stroke (Ritter, Orozco, Coull, McDonagh, & Rosenblum, 2000). Design 
of microfluidic channels to isolate leukocyte-leukocyte or leukocyte-platelet adhesion by 
laying down a layer of platelets within a microfluidic channel may improve understanding 
of leukocyte accumulation in thrombus formation. Another area of application may be 
three-dimensional cell culture, particularly of tumor cells (Kim, Yeon, & Park, 2007; Wu, 
Di Carlo, & Lee, 2008). The present analysis may be used to provide geometric constraints 
for the culture of tumor spheroids for cancer and metastasis research.  
 Finally, particulate-particulate and particulate-surface interactions are of critical 
importance to the transport of colloids in which the suspended particles may adhere to 
channel walls resulting in fouling and blockage. Colloidal fouling is observed in many 
processes, ranging from biological applications as described here to industrial processes 
and devices like filtration, papermaking, heat exchangers, and oil pipelines (Adamczyk, 
Siwek, & Szyk, 1995). Indeed, the mitigation of colloidal fouling is of perhaps greater 
importance in microfluidic systems where relatively small volumes of particle deposits 
may result in channel blockage (Mustin & Stoeber, 2010). The analysis described in the 
present work may be applied to design microfluidic channels to investigate a multitude of 
fouling processes by separating the mechanisms of particulate-surface and particulate-
particulate deposition and adhesion. For a relevant application, the algebraic equations 
presented may be applied by specifying the correct particle characteristics, namely a and 




The present analysis of platelet accumulation has several limitations. For a given 
analysis condition, all platelets were assumed to have the same shape and adhere in the 
same orientation though in physical experiments, platelet shape and adhesion orientation 
may vary. Additionally, only the extremes of platelet adhesion orientation were analyzed. 
Cell and clot deformability and mechanics were not modeled. Coagulation and fibrin 
formation was not considered in the present analysis, nor were the possible effects of other 
clotting proteins, such as von Willebrand factor, considered. Incorporation of erythrocytes 
in the thrombus was not modeled nor was the adhesion of leukocytes considered. The 
presence of other clot constituents were accounted for by including the percent of the 
thrombus composed of platelets, p, in the analysis. Additionally, the present analysis does 
not account for the effects of hemodynamics environment, platelet activation, coagulation, 
biomolecular interactions, or time dependence. Rather, the present study characterizes 
microfluidic channels based on the type of platelet interactions, regardless of the 
underlying mechanisms. This type of characterization may aid in classifying previous 
experimental results based on platelet interaction type and may be used in the design of 
future microfluidic flow assays to isolate the interaction of interest. 
 
3.2.5 Conclusion 
Geometric analysis of thrombus formation in microfluidic test sections showed that test 
section size and thrombus volume strongly affect the proportion of platelet-platelet and 
platelet-surface interactions in platelet adhesion and aggregation assays. Though platelet 
size and shape affect platelet-platelet to platelet-surface interaction ratio and percent 
platelet-platelet interaction, comparison of likely platelet adhesion orientations and Monte 
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Carlo simulation of normal human platelet size distribution suggests that quantitative 
algebraic relationships and a spherical platelet shape assumption are sufficient to classify 
platelet aggregations studies as either dominated by platelet-platelet or platelet surface 
interactions. The relationships obtained from the present analysis may be used to design 
microfluidic test sections to separately investigate platelet-surface adhesion and platelet-
platelet accumulation. In square (low aspect ratio) and round test sections, a height or 
diameter 90 m is necessary for channel occlusion to be dominated by platelet-platelet 
interactions (R > 10). The required height for R > 10 may be decreased to 50 m for 
rectangular aspect ratios ≥ 10. Analytical results were supported by experiments comparing 
two test sections of different sizes and shapes, but both with R > 10. The derived equations 
may be extended to microfluidic and nanofluidic test section design for other types of cell 
adhesion and aggregation, three-dimensional cell culture, and colloidal fouling 
applications. 
 
3.3  Fluid Mechanic Design 
The most physiologically relevant cross sectional shape for assessing arterial thrombus 
formation is circular. Circular cross sections also have the advantage of uniform shear 
around their full circumference. However, circular microfluidic test sections present 
several challenges and limitations, in particular manufacturing complications and optical 
distortions when imaging. Since experimental evidence suggests that platelet accumulation 
is strongly dependent on shear rate, analyses were performed to define a rectangular test 
section such that 90% of the collagen-coated long boundary was within the wall shear 
range of interest, 3500-6000 s-1. Considering Poiseuille flow in a rectangular duct 
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(Papanastasiou, Georgiou, & Alexandrou, 1999) (see Figure 3-10 for geometry and 
boundary conditions), and solving for shear rate gives 
  



























































where  is the fluid viscosity, xP   is the pressure gradient, and b and c are the channel 
half-width and half-height, respectively. For a known flow rate, Q, the pressure gradient 
is 































  (3-26) 
A parameter sweep of eq. (3-26) over h, w, and Q was performed for k = 1-5 using Matlab 
to isolate combinations that met the shear criteria above. The minimum w and Q meeting 
the shear requirement for each h investigated are shown in Table 3-5. 
 
 







Table 3-5: Results of parameter sweep for Poiseuille flow in rectangular duct 
h (m) w (m) Q (m3/s, mL/min) 
50 400 7.35e8,    0.041 
65 450 1.41e9,    0.085 
70 475 1.72e9,    0.103 
75 500 2.10e9,    0.126 
80 500 2.10e9,    0.126 
90 500 3.20e9,    0.192 
100 600 4.86e9,    0.292 
 
 Given the small dimensions of the proposed test section, the Fahraeus-Lindqvist 
effect may result in altered apparent viscosity of the blood. The Fahraeus-Lindqvist effect 
is the observation that blood flowing in small capillary tubes has a lower apparent viscosity 
(Fåhræus & Lindqvist, 1931). This is the result of the formation of a cell-free plasma 
skimming layer close to the wall with a lower viscosity than whole blood. In very small 
tubes, the apparent viscosity increases as red blood cells must squeeze through the tube. In 
the present design, the apparent viscosity affects the pressure-driven flow rate through the 






  (3-27) 
where Δp is the pressure drop across the test section and R is the hydraulic resistance of 
the test section. R scales as 1/μ, where μ is the apparent viscosity, and the wall shear rate, 
γ, is directly proportional to Q. Using the empirical correlations of Pries, Secomb, and 
Gaehtegens (1996), the apparent viscosity for the dimensions used in the present device is 
expected to range from 2.5-3.5 × 10-3 Pa-s. Propagating this viscosity variation through 
the scaling above for a device designed to yield a maximum shear rate of 6000 s-1 for a 
constant blood viscosity of 3.5 × 10-3 Pa-s, as was used here, shows that the corrected shear 
rate due to the Fahraeus-Lindqvist viscosity reduction (worst-case) is expected to be  
94 
 
8400 s-1. Previous studies have shown that thrombus growth rate and lag time are about 
equal at these shear rates (Bark et al., 2012; Mehrabadi, 2014), so no correction in was 
applied. 
  
3.4  Thrombus Growth Considerations 
For a thrombosis device to be clinically useful, it should require a low blood volume (<10 
mL) and provide results quickly. The projected occlusion time (test time) and required 
blood volume were calculated for each geometry under consideration. Previous results for 
rate of thrombus growth under different shear rates were used (Bark et al., 2012). In 
particular, the time for the thrombus to reach a thickness of 10 m, the “lag time,” tlag, 
depends on initial wall shear rate, 
i  and was calculated in seconds as 
  2.0718  ilagt   (3-28) 
Since the wall shear rate varies across the rectangular channel, the mean shear rate was 
used in eq. (3-28). For thrombus growth after the lag time, thrombus deposition was 
simulated in 0.1 s time steps. At each time step, the shear rate, , was computed from  
eq. (3-25) for the shrinking lumen. Then the thrombus deposition rate, J, in m3/m2-min 





















.  (3-29) 
 The simulation was continued until the residual lumen had decreased to 0.1% of 
the initial height to yield the estimated occlusion time. The total occlusion time was 
obtained by adding the lag time, and the estimated blood volume was calculated by 
multiplying the flow rate by the total occlusion time. This method assumes that flow rate 
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is constant and the thrombus grows uniformly. Table 3-6 summarizes the results for 
estimated occlusion time and blood volume for the geometries under consideration. It was 
specified that the estimated blood volume should be less than 1 mL to allow for multiple 
tests from a single 10 mL blood draw, and the total occlusion time should be greater than 
5-7 minutes to permit observation of rapid platelet accumulation described previously (Para 
et al., 2011). The selected channel geometry is highlighted. 
 














50 400 7.35e8,    0.041 6.5 0.286 
70 475 1.72e9,    0.103 8.4 0.867 
80 500 2.10e9,    0.126 9.1 1.146 
90 500 3.20e9,   0.192 10.4 1.998 
100 600 4.86e9,    0.292 11.4 3.325 
  
The height of the non-stenosed regions of the test section were selected so that at 
least 85% of the long boundary had wall shear rates from 500-1000 s-1, healthy arterial 
shear rates, with the same flow rate. Using eq. (3-25) and the same methods described 
above, the non-stenosed channel height was selected to be 170 m. In summary, the test 
section was specified as 475 m wide, 70 m high in the stenotic section, 170 m high at 
the non-stenotic section. 
 
3.4.1 Validation of Thrombosis Model 
After the microfluidic device was fabricated (see Section 3.5 ), test sections were measured 
to have a mean stenotic height of 83 μm. Test sections were incubated for 24 hours prior 
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to experimentation with 0.1% equine collagen Type 1 (Chronopar; Chronolog, Inc.; 
Havertown, PA). Collagen has been shown to adsorb much more readily onto glass than 
PDMS (Li, 2013), resulting in a thrombogenic surface only on the glass bottom of the 
channels.  
 Whole blood was collected from 7 health volunteers under a protocol approved by 
the Georgia Institute of Technology IRB. Blood was anticoagulated at 15.8 USP unit/mL. 
The whole blood was filtered at 60 µm to remove any debris and microaggregates and was 
then perfused through the microfluidic test section under a constant pressure of 684 Pa. 
The discharge mass was measured using an electronic balance, and occlusion time was 
defined as when the discharge mass ceased to increase. 
 The computational model described above predicted an occlusion time of 5.4 min 
in the microfluidic set up, which compares favorably to the mean occlusion time of  
5.7 ± 2.3 min obtained from experiments (Figure 3-11), which shows excellent agreement 
between the computational and experimental results. 
 
Figure 3-11: Predicted (black) and experimental (gray) occlusion times for thrombus 





3.5  Test Section Fabrication and Design for Manufacturing 
Since the test section was design to be fully disposable, both laboratory fabrication and 
large-scale manufacturability were considered. Polydimethylsiloxane (PDMS) is widely 
used for the fabrication of microfluidic devices in the laboratory (Sackmann, Fulton, & 
Beebe, 2014), owing to its quick curing and ability to mold microscale features. The cured 
PDMS test section supplies three sides of the microfluidic test section, with the fourth side 
provided by glass plasma-bonded to the PDMS. The glass provides a substrate for collagen 
functionalization in the test section. See APPENDIX C for detailed fabrication protocol. 
However PDMS is not suitable for injection molding, a widely used and cost-effective 
large-scale manufacturing method (Mayor, J. R., personal communication, 2012). Injection 
molding is also not ideal for the laboratory setting due to the large equipment required. 
Thus, we aimed to develop a microfluidic mold which could be used in the laboratory to 
cast PDMS and which would serve as a template for future injection molding designs. 
Given the length scales identified in the preceding sections, micromachining, rather than 
soft lithography (applicable for length scales <50 μm), was selected as the mold fabrication 
technique, similar to Li et al. (2012). 
 The remaining specification in the test section was the transition from the 
physiological to pathological shear regions. A simple step was excluded from consideration 
due to the extremely high and low wall shear rates induced at the outside and inside corners, 
respectively. A sloped transition was considered, with the option of adding fillets at the 
outside corners. The maximum allowable shear rate at the corners was specified at  
10 000 s-1. The effects of the transition from the non-stenotic region to the stenotic region 
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on shear rate was investigated using numerical modeling (COMSOL 4.2; COMSOL, Inc.; 
Burlington, MA). Two-dimensional simulations were performed for slopes, α, of 15°, 30°, 
and 45° with fillet radii, r, at the corners of 0, 25, 50, and 100 m (see Figure 3-12). 
Simulations were performed on approximately 400 000-element meshes (element size  
~2.2 μm) with a velocity inlet boundary condition corresponding to the average velocity 
calculated from the flow rate in Table 3-5 and a zero-pressure outlet condition. Of critical 
importance was the estimated wall shear rate at the outside corners of the test section, where 
shear concentrations are expected. 
  
 
Figure 3-12: CFD geometry and variables 
 
 
 The shear rate along the upper wall was plotted versus arc length along the 
boundary to identify regions of shear concentrations, and the maximum wall shear rate for 
each condition was isolated (Figure 3-13). The results show a wall shear rate within the 
stenotic region of approximately 4400 s-1, which meets the design criteria of shear rate 
between 3500 and 6000 s-1. At the corners, peak shear rates reached as high as 16 000 s-1 
in the case of α = 45° and r = 0. It was decided that for the peak shear rate should not 
exceed 10 000 s-1 to maintain the test conditions within the range of interest. For α = 15°, 
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the shear rate did no exceed 8000 s-1 for any value of r, so a test section with that geometry 
will be manufactured to eliminate the need for an additional machining operation to add 
fillets in the mold. 
 
 
Figure 3-13: Maximum wall shear rate results obtained by CFD modeling 
 
 
 Following mold fabrication, the channel molds were measured used scanning 
white-light interferometry (Zygo OMP 0365E) (measurements performed by M. 
McMeekin). The eight channels in the mold have a mean stenotic height of 82.4 µm, a 
width of 480 µm, and a non-stenotic height of 182 µm (Mayor J. R. and McMeekin M., 
personal communication, 2012). 
 
3.6  Image Processing 
A non-contact, non-additive method of thrombus detection is advantageous in the point-
of-care setting to allow for easy cleaning and minimal sample handling. A previous study 
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demonstrated that transmitted light through a growing thrombus increased in intensity over 
the course of the experiment and was useful for detecting occlusion (Li et al., 2012). 
However, this method did not provide an estimate of the physical volume of thrombus in 
the test section and was unable to provide real-time thrombus volume data. In the present 
work, confocal microscopy was used in conjunction with transmitted light microscopy to 
determine a relation between the thrombus height at a location and the light transmitted at 
that location.  
 
3.6.1 Methods 
Whole human blood was collected under a protocol approved by the Georgia Institute of 
Technology Institutional Review Board. Blood was anticoagulated with 3.5 USP units/mL. 
The blood was mixed with mepacrine at 10 µM final concentration to fluorescently label 
platelets (Savage et al., 1998). The blood was then perfused through the test section 
designed and fabricated as described in the preceding sections and incubated with 0.1% 
equine collagen Type 1 (Chronopar; Chronolog, Inc.; Havertown, PA). During the 
experiment, confocal microscopy stacks were collected (LSM 700; Carl Zeiss Microscopy; 
Jena, Germany) under 488 nm laser illumination. Transmitted light images (no confocal 
pinhole) were acquired simultaneously. The confocal image stacks spanned the full height 
of the channel, with slices 0.89 µm apart. Each stack took 1-2 minutes to acquire.  
 Confocal image stacks were processed with an in-house program (R2012a; The 
Mathworks, Inc.; Natick, MA) to determine the height of thrombus at each x-y pixel 
location. For each time point, the confocal image stack was read into the program. A 
Gaussian blur was applied, and every voxel identified as either thrombus or not thrombus 
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based on an intensity threshold of 5% of the maximum intensity for detecting the mepacrine 
labeled platelets. Outlying positive voxels were exclude by requiring that identified 
thrombus must occupy at least 4 voxels within a 5 voxel radius. From the binary matrix of 
thrombus location, the height of each thrombus was calculated from the number of slices 
with detected thrombus and the slice thickness. Next, the thrombus height was correlated 
to the change in transmitted intensity (subtracting the intensity in the first time point) in 
the most in-focus slice in the transmitted light stack using a logarithmic fit.  Subsequently, 
three additional confocal experiments were performed to validate the interpolation method. 
The goodness of the interpolation was evaluated using an ANOVA analysis between the 
volume in each stack calculated from the confocal images and the volume interpolated 
from the fit. 
 
3.6.2 Results 
Figure 3-14 shows the growing thrombus using confocal microscopy and transmitted light. 
As the thrombus volume increases (top row, green), the transmitted light (bottom row, 
white) also increases. It should also be noted that the thrombus grows from the bottom, 





Figure 3-14: Thrombus formation visualized using confocal microscopy. Top row: 3D 
renderings of platelet accumulation. Bottom row: Corresponding transmitted light images 
showing an increase in transmittance as thrombus grows. Time points are at initiation of 
flow (A, E), 7.7 min (B, F), 15 min (C, G), and 21 min (D, H) 
 
 
680 000 data points were obtained from the confocal experiment. The average 
transmitted intensity for each thrombus height is shown in Figure 3-15. There is a clear 
increase in transmittance with thrombus height, but large standard deviation. A logarithmic 
fit was perform (Figure 3-16) to interpolate the thrombus height from the change in 
transmitted intensity. The R2 value was 0.90. For transmitted intensity changes less than 
0.019, the corresponding height showed high variability, so all transmitted intensity 
changes less than 0.019 are assigned the mean thrombus height for those values of  
3.115 µm. Converting the equation shown in Figure 3-16 to micrometers and applying the 












h  (3-30) 
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where h is the interpolated thrombus height in µm and ΔI is the change in transmitted 
intensity. Applying eq. (3-30) to three subsequent data sets obtained as the first yielded the 
interpolated total volumes in the region of interest shown in Figure 3-17, plotted versus the 
volume obtained from confocal microscopy, treated here at the gold standard. ANOVA of 
the correlation between the confocal and interpolated volumes gives an adjusted R2 of 0.79 
and an f-value of 1.2 × 10-11. The coefficient is 1.11, very close to unity, and the standard 





















The volume interpolation correlating transmitted intensity to confocal thrombus volume 
yielded acceptably adequate results within 20% for most time points. The interpolation 
may be applied to standard light microscopy (see APPENDIX B for MATLAB code) by 
filtering the incident light at a similar wavelength as used in the confocal experiments  
(488 nm). When applied to light microscopy, the accuracy of the interpolation is limited 
by the increased light scattering caused by the non-coherent light source. Processing over 
2000 images using the present method takes less than 30 minutes, opening the possibility 
of rapid image processing following thrombus formation in a similar device. 
 
3.7  Characterization of Thrombus Formation in the Test Section 
3.7.1 Methods 
Whole blood was collected from 15 normal volunteers under a protocol approved by the 
Georgia Institute of Technology IRB. Subjects had no history of bleeding or thrombotic 
disorders and had not taken aspirin in the previous 10 days. Blood was collected in standard 
10 mL green-top blood collection tubes (BD VacutainerTM; Becton, Dickinson, and 
Company; Franklin Lakes, NJ) and anti-coagulated at 15.8 USP units/mL heparin. Test 
sections were fabricated as described in Section 3.5 and incubated for 24 hours with  
0.1% collagen (Chronopar; Chronolog, Inc.; Havertown, PA). 
The collagen-coated microfluidic chips were installed in the experimental set up 
shown in Figure 3-18. The microfluidic channels were connected to an upstream reservoir 
at a height of 65 mm using 260 mm Tygon lab tubing (1/16 in.; Saint-Gobain North 
America; Valley Forge, PA) using connectors cut from rigid PTFE tubing (1.35 mm; Cole-
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Parmer; Vernon Hills, IL). Downstream tubing and connectors led to a discharge reservoir 
placed on a precision balance (EP213C, Ohaus Corp.; Parsippany, NJ) to measure 
discharge mass. Up to 5 mL of blood was allowed to flow under a constant pressure head 
through the channel. Images of thrombus formation were acquired ever 500 ms using a 
microscope (DM6000 B; Leica Microsystems; Wetzlar, Germany) fitted with a high-
resolution CCD camera (Pixelfly; PCO; Kelheim, Germany). Image acquisition was 
facilitated by the μManager open-source microscopy software (Edelstein, Amodaj, 
Hoover, Vale, & Stuurman, 2010). Occlusion time, tocc, was measured as the time from 
first blood contact with the stenosis to the time when the balance mass stopped increasing 
for at least 1 minute. The experiment was repeated a total of 3 times for each subject. 
 
 
Figure 3-18: Experimental set-up from microfludic tests 
 
 
 Microscopy images were analyzed using MATLAB (R2013b; The Mathworks, 
Inc.; Natick, MA). First images were converted from 16-bit black-and-white to 8-bit color 
using the algorithm provided by the camera manufacturer ("Pixelfly, Pixelfly qe Operating 
Instructions,"). For analysis, the total intensity of the three color channels was used. A 
rectangular region of interest comprising the stenotic region was manually selected, and 
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the total intensity (arbitrary units, AU) increase since the reference images was computed 
for each time point. The reference images was selected as the image 30 sec after blood first 
contacted the channel. The lag time, tlag, was defined as when the mean intensity over the 
region of interest increased by 100 AU. Alternatively, the image analysis method 
developed in Section 3.6 was used to estimate lag time. In this case, tlag was defined as 
when the mean thrombus volume exceeded 3.14 μm3/μm2.  The time between tlag and tocc, 
Δt, was also calculated. The thrombus growth rate, dV/dt, was computed as the slope of the 
linear regression of mean thrombus volume versus time from tocc to tlag. 
 
3.7.2 Results 
Figure 3-19 show typical thrombus growth profiles for both the volume interpolation 
method described in Section 3.6 and for change in transmitted intensity. In both cases, there 
is a period of relatively slow thrombus growth corresponding to the lag time, followed by 
rapid thrombus growth leading to occlusion. The rapid increase in intensity in the period 
after occlusion at 11. 5 min is likely due to an increase in the transmissivity of the thrombus 





Figure 3-19: Characteristic Thrombus Growth: Left - interpolated average volume, Right - 
mean transmitted intensity change, tocc = 11.5 min 
 
 
 The occlusion time was measured for each subject in 3 different experimental runs 
in separate microchannels (Figure 3-20). The average intrasubject variability was 28%, 
ranging from 3% to 61%. Intrasubject variability for PFA-100® has been reported as 28% 
(Poulsen et al., 2007). Intrasubject variability may be improved for the present device by 
compensating for small variations in channel dimensions. 
 
 
Figure 3-20: Occlusion times for n = 15 subjects, repeated 3x (circles, diamonds, and 





Thrombus growth rate determined by the volume interpolation method for the 15 
subjects tested is shown in Figure 3-22. Intrasubject variability ranges from 8% to 102%, 
with a mean of 43%. Figure 3-23 show the lag times and time between lag time and 
occlusion time using both the volume interpolation method (top row) and transmitted light 
method (bottom row). Using the volume interpolation method, the intrasubject variability 
for lag time was between 2% and 95% with a mean of 46%. Using the transmitted light 
method, the variability was between 1% and 68% with a mean of 18%. For the volume 
interpolation method, Δt had an intrasubject variability of between 6% and 64% with a 
mean of 28%. For the volume interpolation method, Δt had an intrasubject variability of 
between 3% and 76% with a mean of 31%. 
 Taking all normal experimental occlusion times (45 total from 15 subjects) together 
gives a mean occlusion time of 12.2 min with a standard deviation of 5.1 min. The 
experimental distribution and the simulated normal distribution based on the mean and 
standard deviation are shown in Figure 3-21. All but one test falls within two standard 





Figure 3-21: Distribution of all normal experimental results (n = 15, in triplicate, 45 total) 
and simulated normal distribution based on experimental mean and standard deviation. 
 
 
 Intrasubject variability may be due to variations in channel dimensions. Due to 
inherent variations in machining processes, the height of the stenosis varied from 76.5 μm 
to 85 μm between the 8 independent test channels. Based on the simple thrombosis model 
outlined in Sections 3.3 and 3.4 , the shear rate may be expected to vary by 8.8% between 
the channels, leading to an expected variation in the occlusion time of 12.6%, 
approximately half the variation observed in experiments. Additional variation is likely due 
to experimental variability between runs. The variation between test channels may be 
reduced by either improving machining techniques, which is quite difficult given the small 
scale and already tight tolerances, or by accounting for channel variations with a correction 
factor. The implementation of the volume interpolation method described in Section 3.6 





Figure 3-22: Thrombus growth rate using volume interpolation method for n = 15 subjects, 
repeated 3x (circles, diamonds, and triangles); black squares represent the means of three 
trials and the error bars show standard deviation. 
 
 
Figure 3-23: Lag time (left) and time from lag time to occlusion time (right): (a-b) using 
volume interpolation method, (c-d) using trnsmitted intensity method; repeated 3x per 
subject (circles, diamonds, and triangles); black squares represent the means of three trials 





3.8  Summary 
In the present work, a novel microfluidic assay for high shear thrombosis was developed. 
Special consideration was given to the fluid dynamic conditions and geometric constraints 
to ensure large-scale thrombus growth. An image processing approach was developed to 
obtain volumetric thrombus growth from transmitted light images. Thrombus formation in 
the test section was characterized for 15 subjects with 3 test cases each. The current design 
may be improved by accounting for variation in channel dimensions. For clinical use, the 
test section should be incorporated into an automated fluid handling system to interface 
with a blood collection tube. The developed test section was utilized in the following 
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CHAPTER 4: CONTRIBUTION OF PLASMA AND PLATELET VON 
WILLEBRAND FACTOR TO OCCLUSIVE HIGH SHEAR THROMBOSIS 
 
4.1  Introduction 
Myocardial infarction (MI) and ischemic stroke result from rapid, occlusive thrombus 
formation at the site of atherosclerotic plaque rupture (Lilly, 2007). Thrombus formation 
at atherosclerotic lesions occurs at high shear rates (Bark & Ku, 2010; Bark, Para, & Ku, 
2012) and follows distinct pathways (Jackson, 2007). Briefly, collagen exposed by plaque 
cap rupture acts as a thrombogenic surface. At high shear rates, plasma von Willebrand 
factor (vWF) is adsorbed onto the surface. Platelets then bind to vWF at the A1 domain via 
platelet receptor GPIb. Bound platelets are activated by shear and/or soluble agonists and 
irreversibly bind via integrin αIIbβ3. Activated platelet release prothrombotic and 
proinflammatory factors, including vWF, initiating a feed-forward amplification of 
thrombus growth. Clinical investigations have indicated that increased vWF levels are 
associated with increased risk of recurrent MI (Jansson, Kilsson, & Johnson, 1991), MI in 
patients with angina pectoris (Thompson, Kienast, Pyke, Haverkate, & van de Loo, 1995), 
and stroke (Wieberdink et al., 2010). On the other hand, low levels of vWF are 
characteristic of von Willebrand Disease (VWD), a bleeding disorder with symptoms 
including nose bleeding, skin bruises and hematomas, prolonged bleeding from trivial 
wounds, oral cavity bleeding, and excessive menstrual bleeding (Sadler et al., 2000). 
 It is well-accepted that platelets are a key constituent of arterial thrombi and vWF 
is critical for platelet adhesion at high shear rates, but few studies have investigated the 
independent role of vWF in large-scale thrombus accumulation, particularly at high shear 
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rates (>3000 s-1) relevant to MI and ischemic stroke. The objective of the present study is 
to determine the relative roles and minimum concentrations of plasma vWF and platelets 
in large-scale occlusive thrombus formation at high shear rates (>3000 s-1).  Previously, we 
have theoretically shown that the number of exposed A1 domains on elongated, netlike 
vWF is likely to be the limiting factor in capturing circulating platelets (Wellings & Ku, 
2012). We thus hypothesize that the contribution of vWF to high shear thrombus formation 
is equal to or greater than that of platelets. Further, we theoretically predicted that the high 
concentration of vWF released from alpha-granules is important to the continued capture 
of platelets as the thrombus narrowed the lumen and shear increased to > 100 000 s-1. Thus, 
we hypothesize that vWF from platelets is important of occlusive high shear thrombus 
formation. To achieve high shear rates with reasonable blood volumes, we employ a 
microfluidic device in conjunction with human-derived blood analogs containing 
controlled vWF concentrations and platelet counts and normal (40%) hematocrit. We also 
consider in vitro thrombus formation in blood from patients with known VWD to study the 
relative contributions of platelet and plasma vWF. The results of this study lead to a better 
understanding of the roles of plasma vWF, platelet vWF, and platelet count in high shear 
thrombosis. 
 
4.2  Methods 
4.2.1 Blood Collection and Preparation 
Blood from normal volunteers was collected under a protocol approved by the Georgia 
Institute of Technology IRB. Volunteers has no history of bleeding or thrombotic disorders 
and had not taken aspirin in the last 10 days. Blood for dilution experiments was collected 
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in 60 mL syringes and anti-coagulated with heparin at 15.8 USP units/mL to match 
standard green-top blood collection tubes (BD VacutainerTM; Becton, Dickinson, and 
Company; Franklin Lakes, NJ). Blood was also collected in 60 mL syringes and anti-
coagulated with acid-citrate-dextrose solution at a 6:1 ratio for platelet isolation. Blood for 
comparison to VWD patient results was collected in standard 10 mL green-top (heparin, 
15.8 USP units/mL) blood collection tubes (BD VacutainerTM; Becton, Dickinson, and 
Company; Franklin Lakes, NJ). Additional blood was collected from all subjects for a 
complete blood count and from select subjects for ristocetin cofactor (VWF:RCo) assays. 
VWF:RCo quantifies the ability of vWF to aggregate platelets. 
 Blood from VWD patients was collected under a protocol approved by the Emory 
University IRB and the Georgia Institute of Technology IRB. Subjects had been previously 
diagnosed with any type of VWD and no platelet defects and were returning to clinic for 
routine follow-up. Blood was collected in standard 10 mL green-top (heparin, 15.8 USP 
units/mL) blood collection tubes (BD VacutainerTM; Becton, Dickinson, and Company; 
Franklin Lakes, NJ). 
 Blood analogs were produced by diluting whole blood from normal volunteers with 
normal saline at 90% and 99% dilutions. Red blood cells (RBC) were isolated by 
centrifugation and washed twice with normal saline (see APPENDIX D). RBCs were 
filtered under gravity at 38 μm using nylon mesh and added to the dilutions to 40% 
hematocrit, yielding a blood analog with normal RBC count and 10% or 1% of normal 
platelet count and plasma protein concentrations. To test the contributions of vWF to high 
shear thrombosis, vWF (Humate-P®; CLS Behring, King of Prussia; PA) was added at 50, 
100, and 200 IU/dL plasma, corresponding to the normal range of plasma vWF levels 
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(Sadler, 2003). To test the contribution of platelets, platelets were isolated from whole 
blood using a double centrifugation procedure (Cazenave et al., 2004) (see APPENDIX E). 
Humate-P® has been shown to have the same vWF multimer distribution as human plasma 
(Fukui et al., 1988). Platelets were resuspended in Tyrode’s albumin buffer, and platelet 
count was obtained using a hemocytometer. On the hemocytometer, platelets appeared 
discoid and non-aggregated, indicating limited platelet activation before experimentation. 
Platelets were added to the blood analog at 120 000 platelets/μL. Platelets were added to 
the blood analog at 120 000 platelets/μL. Additional experiments were conducted adding 
recombinant human ADAMTS13 (R&D Systems, Inc.; Minneapolis, MN), which cleaves 
vWF (Springer, 2011), at normal concentration (0.75 mg/mL) (Soejima et al., 2006) to 90% 
dilutions with restored vWF. One experiment was conducted with ADAMTS13 added at 
six times normal concentration. All blood analogs were filtered under gravity at 50 μm 
using nylon mesh (McMaster-Carr Supply Company; Elmhurst, IL) immediately before 
experimentation. Table 4-1 summarizes the blood analogs considered. 
 









Normal Whole Blood Control 0% 0 0 
Negative Control   90% 0 0 
Normal vWF and Normal Platelet 90% 100 120 
Normal Platelet Only 90% 0 120 
 Normal vWF Only 90% 100 0 
Low Normal vWF Only 90% 50 0 
High Normal vWF Only 90% 200 0 
Normal vWF and Normal Platelet (99% dilution) 99% 100 120 
Normal Platelet Only (99% dilution) 99% 0 120 




4.2.2 Microfluidic Test Platform 
To obtain high fluid shear rates with small blood volumes, a stenotic microfluidic test 
section was designed. The test section was designed to mimic the shear conditions 
experienced by a platelet as it travels from a health artery into a stenotic region and 
returning to health artery. The eight fabricated rectangular test sections are 480 μm and  
77-85 μm (82 μm mean) deep at the stenosis. The stenotic length is 1 mm. Outside the 
stenosis the channel depth is 182 μm. Perfusion under a constant 65 mm pressure head 
yields wall shear rates across 90% of the width of 3500-6000 s-1 in the stenotic region and 
500-1000 s-1 in the non-stenotic region, corresponding to normal arterial wall shear rates 
(Jackson, 2007). Additionally, the stenotic region was designed to favor large-scale platelet 
accumulation as opposed to surface adhesion by ensuring a sufficiently large volume-to-
surface ratio (test section height >50 μm) (see Section 0). 
The designed test section was fabricated from polydimethylsiloxane (PDMS) (Li, 
Ku, & Forest, 2012). A brass mold was micro-machined according to the design. PDMS 
was poured into the mold, degassed, and heat cured. Inlet and outlet ports were manually 
punched in each channel, and the PMDS chip was mounted on a glass microscope slide 
using plasma bonding. The completed microfluidic chip was allowed to cure at 70-75°C 
for 1 hour and then at room temperature overnight. After full cure, the microfluidic 
channels were filled with 0.1% collagen Type I solution (Chronopar; Chronolog, Inc.; 
Havertown, PA) and incubated for 24 hours (Bernardo et al., 2004). Collagen Type I was 
selected to mimic extracellular matrix exposed by atherosclerotic plaque rupture. De Witt 
et al. (2014) showed that collagen Type I is among the most potent platelet-adhesive 




4.2.3 Data Acquisition and Analysis 
The collagen-coated microfluidic chips were installed in the experimental set up shown in 
Figure 4-1. The microfluidic channels were connected to an upstream reservoir at a height 
of 65 mm using 260 mm Tygon lab tubing (1/16 in.; Saint-Gobain North America; Valley 
Forge, PA) using connectors cut from rigid PTFE tubing (1.35 mm; Cole-Parmer; Vernon 
Hills, IL). Downstream tubing and connectors led to a discharge reservoir placed on a 
precision balance (EP213C, Ohaus Corp.; Parsippany, NJ) to measure discharge mass. Up 
to 5 mL of blood or blood analog was allowed to flow under a constant pressure head 
through the channel. Images of thrombus formation were acquired every  
0.5 second using a microscope (DM6000 B; Leica Microsystems; Wetzlar, Germany) fitted 
with a high-resolution (1392 × 1020 pixels) CCD camera (Pixelfly; PCO; Kelheim, 
Germany). Image acquisition was facilitated by the μManager open-source microscopy 
software (Edelstein, Amodaj, Hoover, Vale, & Stuurman, 2010). Occlusion time, tocc, was 
measured as the time from first blood contact with the stenosis to the time when the balance 
mass stopped increasing for at least 1 minute. Blood from normal subjects collected in 
blood collection tubes was tested three times to characterize the experimental platform.  
Microscopy images were analyzed using MATLAB (R2013b; The Mathworks, 
Inc.; Natick, MA). First images were converted from 16-bit black-and-white to 8-bit color 
using the algorithm provided by the camera manufacturer. For analysis, the total average 
intensity (grayscale) of the three color channels was used. A rectangular region of interest 
comprising the stenotic region was manually selected, and the total intensity (arbitrary 
units, AU) increase since the initial reference image (when blood first contacted the 
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channel) was averaged over the area was computed for each time point. To assess the 
phases of thrombus formation, lag time, tlag, was determined as the time at which the total 
intensity increased by 100 AU within the region of interest, starting 30 s after first blood 
contact with the stenosis. Rapid growth time, tg, was calculated as the occlusion time minus 
the lag time. 
 
 
Figure 4-1: Microfluidic experimental set-up. A) diagram overall set-up, B) components 
of experimental set up, C) photograph of experimental set-up, D) diagram of microfluidic 
test section (width is 480 μm into page), E) photograph of microfluidic chip 
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4.2.4 Statistical Analysis 
Data is shown as mean ± standard deviation throughout. Statistical significance was 
evaluated at the 0.05 level, and data analyses were performed using SAS 9.3 (Cary, NC) 
and R Project (Vienna, Austria). Rates of occlusion and thrombus were calculated using 
frequencies and percents within control and successive blood dilation samples. Rate 
comparisons for occlusion and thrombus (yes vs. no) were made using an exact form of the 
Chi-square goodness of fit test. Time to occlusion was gauged across control and blood 
dilution groups using Kaplan-Meier curves and log-rank tests. Log-rank p-values were 
calculated overall and for each pairwise comparison using the Holm-Bonferroni method 
(Holm, 1979). Samples that did not occlude were censored after 35 minutes of follow-up. 
Univariate and multivariable logistic regression was employed to identity significant risk 
factors associated with occlusion.  Potential predictors included platelet counts and vWF 
at baseline and after dilution. Model fit was guided by backward elimination techniques 
and non-significant variables were systematically removed, provided the model fit did not 
substantially change. Adjustments were made for within-sample, correlated data using 
Generalized Estimating Equations (GEEs). Model fits were assessed via receiver operating 
characteristic curve (ROC) and Quasi-Akaike Information Criterion (QIC) statistics (Pan, 
2001).  
 
4.3  Results 
Characteristic normal thrombus growth in the microfluidic test section is shown in Figure 
4-2. Under grayscale imaging, the test section initially appears black as no thrombus has 
formed (Figure 4-2A). Thrombus begins to appear as patchy bright regions  
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(Figure 4-2B and C). At occlusion, large thrombus deposits are clearly visible throughout 
the stenotic portion of test section (Figure 4-2D). The change in total transmitted intensity 
(average of three color channels) across the test section is shown in Figure 4-2E. Initial 
slow deposition followed by rapid thrombus accumulation is apparent. The final sharp 
increase in intensity may be due to clot contraction as the channel nears occlusion. The 
timescale of the intensity increase is in good agreement with previous results of the 
timescale of clot and platelet contraction of 8-12 min (Jen & McIntire, 1982; Lam et al., 
2011). 
 All syringe-collected control cases led to channel occlusion measured by mass 
flow (n = 12, p < 0.001, Figure 4-3A) with a mean occlusion time of 6.1 ± 2.2 min 
(intersubject variability of 36%). Normal subjects had platelets counts of  
245 ± 66 × 103 /μL (n = 12) and VWF:RCo of 75 ± 69 IU/dL (n = 6). Conversely, none of 
the 90% dilution cases led to channel occlusion (n = 7, p = 0.016), indicating that dilution 
reduces the necessary components of high shear thrombosis to the point of eliminating 
thrombotic occlusion. 90% dilutions with restored platelets and vWF (100 IU/dL) occluded 
the channel in all cases (tocc = 13.7 ± 2.5 min). Restoring platelets in 90% dilutions led to 
occlusion in 2/5 subjects (p = 1) with the remainder showing visible thrombus  
(tocc = 27.2 ± 1.8 min). However, restoring vWF to 100 IU/dL in 90% dilutions restored 
occlusion in 6/7 subjects (p = 0.125), with a mean occlusion time of 16.6 ± 1.4 min. 
Experiments with added ADAMTS13 at normal concentration occluded in 4/5 subjects, 
and occlusion time was not reduced. Adding ADAMTS13 at six times normal 
concentration also did not prevent occlusion (n = 1). Thus, vWF is capable of forming 
occlusive thrombus, even with very low platelet counts (10% of normal). Restoring vWF 
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alone also restored occlusion in more subjects and yielded a more rapid occlusion time than 
restoring platelets alone. 
 
Figure 4-2: Normal thrombus formation in microfluidic test section. The test section 
appears black before thrombus formation and thrombus appears white within the test 
section. The stenotic region is bound by the white lines. Flow is from left to right top to 
bottom. A) at initiation of blood flow, B) at 50% occlusion time, C) at 75% occlusion time, 
D) at full occlusion. The test section appears black before thrombus formation and 
thrombus appears white within the test section. Flow is from top to bottom. E) Change in 
mean transmitted intensity during experiment. Note initial slow-growth phase followed by 
rapid thrombus growth beginning at approximately 30 seconds. Occlusion occurs at the 





Figure 4-3: Thrombotic occlusion in microfluidic test section for 90% dilutions of whole 
human blood with normal additions of vWF and platelets. A) Occlusion times, “No 
Occlusion” indicates that test section did not occlude within 5 mL of blood analog but 
thrombus was visible during test; “No Thrombus” indicates that no thrombus was detected 





Kaplan-Meier analysis (Figure 4-3) showed significantly lower probability of 
occlusion in the cases of 90% dilution comparted to control (p < 0.001, adjusted pairwise 
comparison). Qualitative comparison of 90% dilution with restored vWF (100 IU/dL) to 
90% dilution with restored platelets indicate lower probability of occlusion in conditions 
with decreased platelet count compared to conditions with decreased vWF concentration 
(p = 0.054). The addition of platelets to 90% dilution with normal vWF cases did not have 
a significant effect on occlusion probability (p = 0.073). However, the addition of vWF to 
90% dilution with normal platelet cases significantly increases the probability of occlusion 
(p = 0.006). Multivariable logistic regression for occlusion indicated that the resultant 
platelet count and resultant vWF concentration after dilution are significant predictors of 
occlusion (Table 4-2). The odds ratio (OR) for a 100,000 platelet/μL increase was  
4.43 (95% confidence interval 2.96-6.65), and the OR for a 10 IU/dL increase in vWF is 
1.26 (95% confidence interval 1.10-1.45). A QIC model evaluates the ability of particular 
variables to account fully for the outcome, where a lower number indicates a better fit. The 
QIC model fit statistics were 82.25 for platelet count after dilution and 39.36 for vWF 
concentration after dilution, indicating that vWF concentration after dilution is a stronger 
predictor of occlusion. Not only is vWF capable of forming occlusive thrombus with very 





Table 4-2: Multivariable logistic regression for occlusion (yes vs. no) 
Characteristic OR (95% CI) P-Value QIC Model Fit3 
Platelet count  
(after dilution)  
4.43 (2.96 – 6.65)1 <0.001 82.25 
vWF  
(after dilution) 
1.26 (1.10 – 1.45)2 0.001 39.36 
1OR are based upon 100,000 unit increase in platelet characteristics  
2OR are based upon 10 unit increases in VWF characteristics 
3Smaller values indicate better model fit 
 
 
In 90% dilutions, added vWF was varied from 50 IU/dL to 200 IU/dL (Figure 4-4). 
At low-normal levels of vWF (50 IU/dL), 2/6 subjects occluded (p = 0.688). When  
100 IU/dL vWF was added to 90% dilution, 6/7 subjects occluded (p = 0.125). At high-
normal levels of vWF (200 IU/dL), 6/6 subjects occluded (p = 0.031). Though additional 
vWF resulted in more subjects occluding at each subsequent experimental condition, the 
occlusion times were not affected. 
Surprisingly, 99% dilutions with restored platelets and vWF (100 IU/dL) did not 
lead to thrombotic occlusion (Figure 4-5A). Rather, large-scale thrombus formed, but 
embolized repeatedly without fully occluding the vessel. Figure 4-5B shows the change in 
transmitted intensity for one such case, and rather than rapidly increasing as in Figure 4-2E, 
the curve shows over ten large peaks and valleys over a long experiment time, from 
thrombus growth and detachment rather than occluding. Note that the time scale is in tens 
of minutes to compress the time. Embolization occurs within 60 to 180s. 99% dilutions 
with either restored platelets or restored vWF (100 IU/dL) did not show thrombus 




Figure 4-4: Occlusion times in microfluidic test section for 90% dilutions of whole human 





Figure 4-5: A) Occlusion times in microfluidics test sections for 99% dilutions of whole 
human blood with additions of normal levels of plasma vWF and platelets. “No Occlusion” 
indicates that test section did not occlude within 5 mL of blood analog but thrombus was 
visible during test; “No Thrombus” indicates that no thrombus was detected during the 
experiment; B) 99% dilution with 100 IU/dL vWF and 120 000 platelets/μL forms large 
thrombus but does not form stable occlusive thrombus. Spikes in transmitted intensity 





Blood from VWD patients showed decreased occlusion compared to normal 
controls (Figure 4-6A). All blood tube-collected control cases led to channel occlusion  
(n = 15) with a mean occlusion time of 9.5 ± 3.4 min. Normal subjects had a mean platelet 
count of 275 ± 69 × 103 /μL. VWD patients were separated post hoc into two groups for 
analysis. Severe VWD patients has VWF:RCo < 15, and mild VWD patients had  
15 < VWF:RCo < 50 (Favaloro et al., 2009). VWD patients had a mean platelet count of 
280 ± 109 × 103 /μL. Mild VWD blood occluded in 4/6 subjects tested. Severe VWD blood 
did not occlude in any of the five subjects tested. As a screening test for VWD using a 
threshold of tocc = 11 minutes, the test platform yields a sensitivity of 1, a specificity of 
0.67, a positive predictive value of 0.71, and a negative predictive value of 1. When vWF 
was added in vitro to mild VWD samples, occlusion was restored in the two non-occluding 
subjects, but the occlusion times for the occluding subjects were not shortened. The 
addition of vWF to severe VWD subjects restored occlusion in only one subject. Kaplan-
Meier analysis shows that mild VWD samples and mild VWD samples treated with in vitro 
vWF have a lower probability of occlusion compared to normal subjects (p < 0.01,  
Figure 4-6B). The probability of occlusion between the in vitro treated and untreated 
groups was not statistically different (p = 0.815). Restoring plasma vWF in subjects with 
VWD, that is, in subjects deficient in platelet vWF, does not lead to occlusion. Thus, 




Figure 4-6: Thrombotic occlusion in microfluidic test section for normal subjects and 
VWD patients with and without in vitro added vWF. A) Occlusion times, B) Kaplan-Meier 
analysis of occlusion probability. 
 
 
 Lag times and rapid growth times (Figure 4-7) were calculated for all 90% dilutions 
conditions. Lag time was also calculated for 99% dilution with restored platelets and 
plasma vWF, and rapid growth time was calculated for that condition as the time from lag 
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time to the first intensity spike/embolization event. Lag time for 90% dilutions with both 
platelets and vWF restored were shorter than for dilutions with only platelets or only vWF 
restored but still significantly longer than for the whole blood control (Figure 4-7A). 
Restoring only vWF reduced both lag time and growth rate more than restoring only 
platelets. Rapid growth time and lag time were correlated (R = 0.81). However, restoring 
vWF and platelets did not change rapid growth time over restoring plasma vWF only 
(Figure 4-7B). Figure 4-7C combines the lag times and rapid growth times and shows that 
the portion of total occlusion time quantified by the lag time is greater when only vWF is 
restored compared to when both platelets and vWF are restored. 
 Figure 4-8 shows lag times and rapid growth times for VWD experiments for 
subjects that reached occlusion (tests forming no thrombus cannot be analyzed for lag time 
and non-occluding tests cannot be analyzed for rapid growth time). VWD samples showed 
increased lag time and rapid growth time. Restoring plasma vWF does not have a 





Figure 4-7: A) Lag time and B) rapid growth time for dilutions experiments, C) Combined 
lag and rapid growth times for occlusion experiments. * indicates p < 0.l, ** indicates p < 
0.05 (Student’s t-test). Lag times and rapid growth times were all significantly longer than 





Figure 4-8: A) lag time and B) rapid growth time for VWD experiments 
 
 
4.4  Discussion 
Thrombus formation under high fluid shear rate is mediated by platelets and vWF. In the 
present study, we utilize dilutions of whole blood to demonstrate that large-scale occlusive 
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thrombus can form in microchannels with a normal concentration of vWF with very low 
platelet count. We show that VWF is the primary mediator of high shear thrombosis, and 
vWF concentration is a better predictor of occlusion than platelet count. We also utilize 
blood from patients diagnosed with VWD to show that platelet vWF is important for 
occlusive thrombus formation. 
Human blood diluted to 90% with only normal concentrations of vWF added  
(100 IU/dL) led to thrombotic occlusion in most cases, despite having only 10% normal 
platelet count. Hence, vWF is capable of supporting high shear thrombosis even with very 
few platelets. However, 99% dilutions with added vWF did not result in occlusion in most 
cases, so there is a minimum concentration of platelets necessary for occlusive thrombus 
formation. In these cases, platelets may serve two roles: 1) as nodes for supporting vWF 
binding and 2) as carriers that release vWF stores upon activation. The occlusion times for 
90% dilutions with added vWF were 2.7 times longer than for controls (6.1 ± 2.2 min 
versus 16.6 ± 1.4 min). The increase in occlusion time may be due to the time required for 
sufficient platelets to be transported to the growing thrombus or to a decrease in vWF 
release by platelets. It should be noted, however, that the increase in occlusion time does 
not indicate that an equal number of platelets must be incorporated into the growth 
thrombus as in the whole blood case. For instance, if the same number of platelets were 
required to form occlusive thrombus, one would expect the occlusion time with 10% of 
normal platelet count to be 10 times as long as the whole blood control. The decreased 
platelet requirement may be facilitated by vWF self-assembly (Dayananda, Singh, Mondal, 
& Neelamegham, 2010) and net formation (Colace & Diamond, 2013), both processes that 
are enhanced by high shear rates. VWF nets have been proposed as a mechanism for rapid 
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and efficient platelet capture at high shear rates (Wellings & Ku, 2012) and may facilitate 
thrombotic occlusion in blood analogs with very low platelet counts. 90% dilutions with 
only platelets restored occluded the microchannel in 2/5 cases with occlusion times  
>20 minutes, which closely recapitulates results for VWD samples. However, logistic 
regression showed vWF concentration after dilution was more predictive of occlusion than 
platelet count after dilution. 
Our results are consistent with Ogawa et al. (2013), which showed that 40% 
hemodilution decreased thrombus onset and growth and that adding vWF accelerated 
thrombosis at shear rates of 1100 s-1. However, their hemodilutions also reduced RBC 
count, which is known to reduce diffusive transport (Zydney & Colton, 1988) and slow 
thrombus formation (Mehrabadi, 2014). Additionally, the modest hemodilutions of 40% 
used in the previous study retain high residual concentrations of plasma proteins and 
platelet count. The present study employs higher shear rates more relevant to arterial 
thrombosis, fixed hematocrit (40%) to control for changes in shear enhanced diffusivity, 
and larger dilutions to isolate and analyze the individual contributions of vWF and 
platelets. 
Blood samples from subjects with known VWD were utilized to investigate the 
contributions of plasma and platelet vWF. VWD samples have both low plasma vWF and 
low platelet vWF, whereas diluted samples have platelets with normal vWF content. While 
the in vitro addition of vWF restored occlusion in both non-occluding samples with mild 
VWD (15 < VWF:RCo < 50), vWF addition did not restore occlusion in 3/4 subjects with 
severe VWD (VWF:RCo < 15). Thus, in subjects with very low plasma and platelet vWF 
levels, plasma vWF alone is not sufficient in most cases to restore occlusion, and platelet 
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vWF is important for thrombotic occlusion at high shear rates. Subjects with higher platelet 
vWF levels may be capable of occlusive thrombus formation once plasma vWF levels were 
restored because plasma vWF facilitates the initial capture of platelets, allowing for the 
local release of platelet vWF stores. Though the patients with VWD had no evidence of 
platelet defects, it is possible that undetected defects may exist.  One study showed that 
platelets from VWD subjects had a lower surface density of collagen receptors (Di Paolo 
et al., 1999), and other differences from normal platelets may be possible. Collagen 
receptor density is unlikely to have a strong effect on the results of the present study since 
platelet binding at high shear rate is modulated by vWF and the majority of thrombus 
growth here is not surface adhesion but volumetric accumulation. Another study showed 
that VWD blood perfused over rabbit subendothelium yielded normal platelet adhesion to 
the surface in some cases but reduced thrombus volume growth in the same cases (Turitto, 
Weiss, & Baumgartner, 1984). These results support the conclusion of the present study 
that a moderate concentration of plasma vWF is sufficient for surface-platelet adhesion, 
but vWF release from platelets is required for large-scale thrombus growth.  
Our results support previous modeling that concluded that high vWF local 
concentration facilitated vWF release from platelets is necessary for platelet capture at high 
shear rates (Wellings & Ku, 2012). Our results are in agreement with those of Moake, et 
al. (1988), who used a cone-and-plate model to show that platelet aggregation under high 
shear stress (up to 60 dynes/cm2 or a shear rate of approximately 1700 s-1) is mediated by 
either plasma vWF or vWF released from platelets. Isolated platelets resuspended in buffer 
showed little aggregation, but vWF added to the suspension induced aggregation under 
shear. Severe VWD platelets in buffer showed no aggregation. The present study extends 
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these results to a single-pass system at higher shear rates that better mimics the shear 
conditions of a stenotic artery. Whereas the previous study investigated only small platelet 
aggregates, the present studied used large occlusive thrombus formation as the endpoint to 
better model thrombi responsible for MI and ischemic strokes. The major finding of the 
present study is that normal vWF can lead to thrombotic occlusion even with small platelet 
counts, showing the dominance of vWF in high shear thrombosis. This is even more 
surprising as many would guess that platelet bulk would be critical to creating the mass of 
the thrombus. Taking the results together, it can be concluded that a threshold of plasma 
vWF is necessary to initiate thrombosis at high shear rate and sufficient vWF release from 
platelets may be necessary for large, rapid occlusive thrombosis.  
A previous study in mice showed that plasma vWF alone could support hemostasis 
based on tail bleeding time, and platelet vWF could reduce bleeding time in some vWF-
deficient mice (Kanaji, Fahs, Shi, Haberichter, & Montgomery, 2012). Microfluidic 
experiments in the same study showed that either plasma- or platelet-derived vWF 
supported platelet adhesion to a collagen surface under shear rates of 2000 s-1. The results 
of the present study show that while plasma vWF alone may be able to support surface 
adhesion of platelets in the formation of hemostatic platelet plugs, platelets containing vWF 
are necessary for large-scale occlusive thrombus at high shear rates. In particular, vWF 
release from platelets may be necessary to support the rapid thrombus growth that leads to 
thrombotic occlusion by increasing the local concentration of vWF. Platelet-derived vWF 
has also be shown to have a higher molecular weight distribution than plasma vWF, which 
are more hemostatically active (McGrath et al., 2013). The same study showed that vWF 
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released by platelets is resistant to cleavage by ADAMTS13, which may further contribute 
to rapid thrombus growth leading to occlusion. 
Surprisingly, when all other plasma proteins are diluted to 1% of their normal 
concentrations and vWF and platelets are restored, stable occlusive thrombus does not 
form, though large thrombus forms and embolizes. These results suggest that an addition 
plasma protein(s) is necessary for thrombus stability and occlusion. Maxwell et al. (2007) 
noted that stable platelet aggregates do not form at shear rates of 1800 s-1 on a vWF-only 
matrix but do form on a vWF-fibrinogen matrix, indicating that fibrinogen may play a 
stabilizing role in thrombus formation. It is unclear if fibrinogen plays such a role at the 
higher shear rates employed in the present study. Alternatively, Ni et al. (2003) noted that 
stable occlusive thrombus in an arteriole injury model (shear rate ~1200 s-1) did not form 
in most mice deficient in plasma fibronectin, suggesting another potential stabilizing factor. 
Thrombospondin-1 has also been proposed as an alternative high-shear thrombosis-
mediating protein (Bergmeier et al., 2006). Future studies should utilize the present method 
with selective additions of these candidate proteins to determine the critical stabilizing 
factor(s). 
Lag time and rapid growth time were analyzed for select cases to provide insight 
into the mechanisms of the three phases of thrombus growth. The correlation of lag time 
and rapid growth time may indicate that similar mechanisms are at work in each phase, 
namely plasma vWF adsorption, platelet binding, and vWF release from activated platelets. 
Results showed that restoring only plasma vWF reduces lag time more than restoring only 
platelets, which may reflect more rapid adsorption of vWF onto the thrombogenic surface 
due to higher plasma concentration. Restoring both vWF and platelets further reduces lag 
143 
 
time, which may indicate that lag time involves both plasma vWF adsorption and platelet 
capture and activation. In contrast, restoring plasma vWF and platelets was shown to have 
the same effect on rapid growth time as restoring only plasma vWF, indicating that once 
lag time is reached, rapid thrombus growth proceeds at the same rate with either low 
platelet count or restored platelet count. This may indicate that the necessary condition for 
the process to progress past the lag phase and into the rapid growth phase is the adsorption 
of plasma vWF and the subsequent capture and activation of a sufficient number of 
platelets. In the case with only plasma vWF restored, it takes longer for the threshold 
number of platelets to be captured and activated due to the lower platelet count. However, 
once the captured platelets activate, the feed-forward mechanism of platelet vWF release 
may sustain rapid thrombus growth. This may reflect a combination of vWF self-assembly 
and net formation and very efficient capture of platelets by the vWF network. This notion 
of the requirement of vWF release from platelets for progression past lag time is further 
supported by the lag time and rapid growth time results for VWD samples in which 
restoring plasma vWF does not affect lag time or rapid growth time. A reduction in vWF 
release from VWD platelets may act to both restrain the process to the lag phase and reduce 
the positive feedback of rapid growth. It is important to note that the most severe VWD 
samples did not progress out of lag time, even with restored plasma vWF. The transition 
from lag time to rapid growth time by vWF release from platelets is consistent with the 
timescales of platelet activation, with platelet integrin activation occurring in seconds 
(Frojmovic, Wong, & van de Ven, 1991; Shattil, Kashiwagi, & Pampori, 1998; Takagi & 
Springer, 2002), platelet alpha- and dense-granule release occurring in about 1 minute 
(Kaplan, Nossel, Drillings, & Lesznik, 1978), and platelet spreading beginning in  
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2-5 minutes (Kulkarni & Jackson, 2004). Note that lag time for normal subjects is  
48 ± 11 s, on the same timescale as granule release. 
The results of the present study have clinical implications for the prevention of 
arterial thrombosis. Presently, anti-platelet agents, primarily aspirin and P2Y12 inhibitors 
(e.g. clopidogrel, prasugrel, and ticagrelor) are the treatments-of-choice for long-term 
therapy for their relatively low cost and oral administration. That thrombus may form with 
only 10% of normal platelet count may explain some of the documented aspirin and 
clopidogrel non-response (Gum, Kottke-Marchant, Welsh, White, & Topol, 2003; Mueller 
et al., 2003). The effectiveness of these therapies in many patients may be in part the result 
of decreased platelet activation leading to decreased vWF release from platelets. Non-
responsiveness may also be due to platelet activation via alternative pathways, such as 
shear (Hellums, Peterson, Stathopoulos, Moake, & Giorgio, 1987; Ramstack, Zuckerman, 
& Mockros, 1979) or GPIb binding (Kroll, Harris, Moake, Handin, & Schafer, 1991). 
Alternative anti-thrombotic agents that target vWF are currently under development 
(Ulrichts et al., 2011) and may provide an additional or alternative treatment for patients 
who are non-responsive to anti-platelet drugs. The present results may also have important 
implications for bleeding in surgery or trauma. In case of severe bleeding with fluid 
replacement via saline, the blood undergoes hemodilution, which can lead to reduced 
hemostasis. Our results indicate that replacing only platelets may be insufficient for 
restoring hemostatic function as plasma vWF may be of greater importance at high shear 
rates. 
The present study has several limitations. Blood was anticoagulated with heparin 
for transport, which reduces the contribution of fibrin formation in thrombus formation. 
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Sodium citrate with subsequent re-calcification instead of heparin could be used to retain 
fibrin formation. For some studies, blood was collected in blood collection tubes, which 
induce higher shear rates and may prematurely activate platelets. This was controlled for 
in the present study, but may lead to differences in thrombus growth and occlusion times 
compared to in vivo thrombosis. The present study did not determine the additional critical 
factors besides vWF and platelets that are necessary for high shear stable thrombus 
formation. Multiple platelet counts and normal platelets in VWD plasma/blood were not 
investigated. Calcium ion concentration was not controlled or restored in hemodilutions, 
which may impair platelet activation. The vWF concentrate (Humate-P®) also contained 
coagulation Factor VIII. The addition of Factor VIII is not expected to have a large effect 
on the results since the blood was anticoagulated with heparin.  
In conclusion, vWF is more contributory to high shear thrombosis compared to 
platelets and other plasma proteins. VWF can support occlusive thrombus formation even 
with low platelet counts, and vWF release from platelets may be important for occlusive 
thrombosis. However, an additional plasma factor(s) may be necessary for stable thrombus 
formation. Greater understanding of the contribution of vWF and a third plasma factor to 
high shear thrombosis may lead to more effective prevention of high shear thrombosis.  
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CHAPTER 5: CONCLUSIONS AND FUTURE WORK 
This dissertation investigated the contribution of vWF and platelets to high shear 
thrombosis relevant to MI and stroke. To accomplish this, a high shear thrombosis assay 
was developed to meet low blood volume requirements and fluid shear conditions while 
allowing for the formation of large-scale occlusive thrombus. Microfluidic conditions were 
selected to mimic the shear environment of a stenotic coronary vessel to address the long-
term objective of a clinical assay. Unlike currently available assays, the present test 
provides for a well-defined shear rate across the full test section and real-time thrombus 
and embolization monitoring in a clinically reasonable blood volume without the addition 
of soluble platelet agonists. 
As part of the design of the microfluidic assay, the effect of flow pulsatility on high 
shear thrombus formation was investigated (CHAPTER 2). It was found that thrombus 
formation characteristics (occlusion time, lag time, and growth rate) under pulsatile flow 
were not statistically different from steady flow under the same mean wall shear rate. When 
the steady wall shear rate was matched to the peak shear rate under pulsatile flow, the lag 
time was significantly shorter than under either mean shear steady flow conditions or 
pulsatile flow conditions. The present results extend the work of van Breugel (1988) to 
higher shear rates relevant to arterial stenosis and indicated that mean wall shear rate is 
among the most important fluid dynamic parameters influencing thrombus growth. These 
results provided evidence to proceed with the design of a microfluidic thrombosis assay 
that utilized steady flow conditions with confidence that the results have applicability to 
arterial flow conditions. 
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Design requirements for a relevant microfluidic assay were specified, including low 
blood volume (<10 mL), wall shear rate that varied from 500-1000 s-1 in the non-stenotic 
region to 3500-6000 s-1 in the stenotic region, and many more (10x) platelet-to-platelet 
binding events than platelet-to-surface binding events (CHAPTER 3). The first 
requirement was necessitated both by the need to assess many experimental conditions in 
the subsequent study of vWF and platelet contributions to high shear thrombosis and by 
the long-term goal of developing a point-of-care assay for assessing thrombosis risk and 
treatment. Wall shear ranges and profiles and occlusive thrombus size were selected to 
mimic the fluid environment and thrombus growth of a diseased coronary artery. The 
minimum channel height (50 μm) and diameter (50 μm) were determined using a geometric 
analysis of platelet accumulation (Casa & Ku, 2014), providing a lower bound for 
microfluidic channel size for the study of volumetric thrombosis. Analytical solutions for 
flow in a rectangular channel were used to determine the minimum channel width and 
corresponding flow rate to ensure that 90% of the channel width had a wall shear rate in 
the range of 3500-6000 s-1. An aspect ratio of ~5.5-6.5 satisfies this requirement. To check 
the reasonableness of assay test times and blood volumes, the time to occlusion was also 
estimated using a simple model of thrombosis (Bark, Para, & Ku, 2012), predicting test 
times of 8.4 min and blood volumes of 0.9 mL, both in good agreement with experimental 
observations. The designed microchannels were then fabricated using micromachining 
techniques to produce a mold used for pouring PDMS. An image processing algorithm was 
also developed using confocal microscopy to correlate transmitted light to thrombus 
volume, allowing for the estimation of thrombus deposition and growth rate. Finally, 
thrombus formation was characterized in the test section for 15 normal subjects with 3 tests 
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each. Occlusion time of the test section has a within-subject variability of 28%, which may 
be improved by accounting for variations in channel dimensions. Future work may also 
aim to integrate the design test section into an automated point-of-care test for assessing 
patient response to therapy and predicting thrombosis risk. It was also shown that blood 
collection via blood collection tube (10 mL Vacutainer®) increased occlusion time 
compared to blood collected in a 60 mL syringe, highlighting the importance of 
standardized blood collection procedures for any platelet function/high shear thrombosis 
assay. 
The present microfluidic assay improves on previous assays by incorporating a 
stenotic test section with controlled shear rates across the length of the test section and 
pathological shear rates in a small blood volume (<5 mL per test). Unlike most previous 
microfluidic thrombosis assays (Gutierrez et al., 2008; Hosokawa et al., 2011; Maloney, 
Brass, & Diamond, 2010; Neeves et al., 2008; Sakariassen, Aarts, & de Groot, 1983; 
Sixma, de Groot, van Zanten, & Ijsseldijk, 1998; Usami, Chen, Zhao, Chien, & Skalak, 
1993), the present device employs a stenotic test section that provides for controlled shear 
rates throughout the test section and mimics the shear history of platelets passing from a 
healthy artery to a diseased portion. Test sections without a stenosis subject platelets to 
high shear rate across the length of the test section, which may induce platelet activation 
before the stenosis, in opposition to the pathological case. Compared to previous stenotic 
microfluidic test section (Li, Ku, & Forest, 2012; Sakariassen et al., 1990), the present 
design considerably reduces both the width and height of the test section, allowing for high 
wall shear rates to be achieved with smaller blood volumes. The reduction in dimensions 
was carefully considered to reduce edge effects across the width of the channel and to 
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ensure that the channel was of sufficient size to allow for volumetric thrombus growth 
rather than primarily platelet adhesion to a surface. The present device was designed to 
operate at higher shear rates (>3500 s-1) than most previous test sections, which have been 
typically used to investigate shear rates <1500 s-1.  
The designed test section was implemented to study the relative contributions of 
vWF and platelets in high shear thrombosis (CHAPTER 4). Most notably, it was found that 
blood analogs with normal hematocrit and normal vWF concentration but only 10% of 
native platelet count were capable of forming thrombus under pathological shear rates. 
However, the rate of thrombus formation was much slower than that of whole blood. This 
finding indicates that vWF dominates high shear thrombosis. Previous results have 
demonstrated that vWF self-associates (Dayananda, Singh, Mondal, & Neelamegham, 
2010) and forms tangled nets (Colace & Diamond, 2013) at elevated shear rates. The results 
here are suggestive that this self-associating and self-adhesion may be capable of forming 
occlusive thrombi. 
 Blood samples from VWD patients with plasma vWF restored to normal levels 
were used to assess thrombus formation in blood with normal plasma vWF levels but no 
vWF release from platelets. In this manner, it was found that plasma vWF alone was not 
sufficient to support rapid occlusive thrombus formation, and vWF release from platelet is 
likely required to achieve very rapid thrombus growth. Previously, it was unclear what 
distinct roles were played by plasma and platelet vWF (Jackson, 2007). Though vWF 
release by platelets was hypothesized as critical for platelet capture under high shear 
(Wellings & Ku, 2012), the present investigation provides experimental evidence for the 
importance of vWF release from platelets in rapid, occlusive thrombosis. It was also 
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demonstrated that the developed assay was capable of detecting VWD. Regression analysis 
showed that vWF concentration and platelet count are predictive of thrombotic occlusion, 
with vWF as the stronger predictor. Finally, blood analogs with plasma proteins reduced 
to 1% of their normal concentrations resulted in large scale thrombus growth that was 
unstable and never fully occluded the vessel, indicating that another plasma protein, 
possibly fibrinogen (Maxwell et al., 2007; Savage, Almus-Jacobs, & Ruggeri, 1998) or 
fibronectin (Ni et al., 2003), is required at least at 10% normal concentration for stable 
thrombus formation. Future studies should be conducted to conclusively identify this 
stabilizing plasma protein and its required concentration for occlusive thrombus formation. 
The findings on the relative roles of platelets, plasma vWF, and platelet vWF have 
important implications in anti-thrombotic treatment. First, it is clear that thrombus can form 
even with very small platelet contribution, which may explain why some patients are non-
responsive to anti-platelet agents (Gum, Kottke-Marchant, Welsh, White, & Topol, 2003; 
Mueller et al., 2003) and still suffer arterial thrombosis even when treated with anti-platelet 
agents. The success of existing anti-platelet agents, which inhibit various pathways of 
platelet activation, may be in part due to their inhibition of vWF release by platelets, 
reducing the high shear positive-feedback loop. Potential pharmacological agents are 
currently under development that target vWF rather than platelets for the prevention of 
thrombosis (Ulrichts et al., 2011) and may prove effective additional or alternative 
treatments for patients who are non-responsive to existing anti-platelet therapies.  
The phenomenon of high shear occlusive thrombosis studied here is distinct from 
mechanisms of platelet activation and aggregation and lower shear thrombus formation 
investigated elsewhere. Many previous studies have limited investigation to shear rates 
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<1500 s-1 (Colace, Muthard, & Diamond, 2012; Flamm et al., 2012; Maloney et al., 2010; 
Neeves et al., 2008; Neeves, Illing, & Diamond, 2010; Okorie, Denney, Chatterjee, Neeves, 
& Diamond, 2008), whereas shear rates in arterial stenoses exceed 5000 s-1 and extend to 
>100 000 s-1 (Bark & Ku, 2010). The dominance of different thrombotic mechanisms at 
elevated shear rates (Jackson, 2007) requires separate study. Other studies have focused 
primarily on the early thrombotic events related to individual or small numbers of platelets: 
platelet adhesion to a surface and platelet activation and effects of shear on platelets (Al-
Tamimi et al., 2012; Cranmer et al., 2011; Lee, Sturgeon, Jackson, & Hamilton, 2011; 
Maxwell, Dopheide, Turner, & Jackson, 2006; Maxwell et al., 2007; Nesbitt, Harper, 
Schoenwaelder, Yuan, & Jackson, 2012; Schoenwaelder et al., 2011; Schoenwaelder & 
Jackson, 2012; White et al., 2012), and platelet binding to vWF (Chen et al., 2013; Ruggeri, 
Orje, Haberman, Federici, & Reininger, 2006). The present study chose to focus on the 
accumulation of millions or billions of platelets under pathological shear in order to 
investigate thrombosis relevant to occlusive arterial thrombosis that leads to MI. Studies 
of individual or small aggregates of platelets confine their analysis to Phase I (lag time) of 
thrombus formation and often do not investigate Phase II (rapid platelet accumulation). 
This dissertation also highlights some key considerations in thrombosis assay 
development. First, appropriate fluid dynamics should be selected to study the phenomenon 
of interest (e.g. deep vein thrombosis, arterial thrombosis, etc.). These include shear rates, 
edge effects, shear history, and flow pulsatility. In the present study, shear rates were 
selected for relevance to thrombosis at the site of atherosclerotic disease, where very high 
shear rates exist over a short extent. The shear range selected represented the “worst case” 
for thrombotic occlusion, i.e., the shear range which had been previously shown to yield 
157 
 
the most rapid thrombus growth (Bark et al., 2012). Second, geometric effects should be 
accounted for. In the quest for ever-smaller lab-on-a-chip assays, there exists a minimum 
dimension below which only platelet adhesion to a surface and not platelet accumulation 
will be observed. Selecting relevant dimensions is key to isolating the phenomenon of 
interest (platelet adhesion versus aggregation).  
Though not extensively investigated here, the surface thrombogenic properties 
should also be considered in flow assays for thrombosis. Here, collagen Type I was selected 
to mimic extracellular matrix exposed by atherosclerotic plaque rupture. However, many 
other surface coatings (vWF, fibrinogen, fibronectin, other collagen types, etc.) have been 
investigated to identify the contributions and synergistic effects of other platelet binding 
surfaces. De Witt et al. (2014) showed that collagen Type I is among the most potent 
platelet-adhesive surfaces under flow, with other biological substrates initiating relatively 
large aggregates of activated platelets. Other potent surfaces included combination coatings 
(e.g. fibrinogen + vWF) that engaged multiple platelet receptors (e.g. GPIb and GPVI). 
Other surfaces that interacted with single receptors produced smaller aggregates of less 
activated platelets. Thus, the present study’s use of collagen Type I again signifies the 
“worst case” scenario for arterial thrombosis, as well as a likely thrombotic substrate given 
its presence in arterial walls. The use of an alternative substrate would be expected to 
reduce early thrombus formation and thus increase the lag time. Beyond the use of native 
thrombogenic surface, future studies should investigate the potential of artificial surface to 
induce thrombosis under flow. Implantable cardiovascular devices, including artificial 
heart valves, vascular grafts, and ventricular assist devices, have serious thrombotic risks. 
Investigating thrombus formation under flow on the materials used in these devices, such 
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as PTFE (Teflon®), PET (Dacron®), pyrolytic carbon, nitinol, and stainless steel, may help 
to identify the most appropriate materials for a design application, reduce thrombotic 
potential by alleviating adverse fluid mechanics, and lead to new material development and 
passivation to prevent thrombosis. The surface characteristics of various materials are most 
likely to affect the lag time (Phase I) of thrombus formation, since once a surface is covered 
in platelets, the positive feedback mechanisms of platelet activation will drive the process 
in to rapid thrombus growth (Phase II) and thrombotic occlusion (Phase III). 
In the search for more effective pharmaceuticals for the prevention of MI and 
ischemic stroke, flow assays may prove useful for drug candidate screening under shear 
conditions relevant to the conditions they are intended to prevent. In the clinic, a flow assay 
for thrombosis may be useful to assessing potential drug therapies for a specific patient and 
determining the effectiveness of and titrating current treatment. This type of testing may 
help identify patients that are not responsive to aspirin or clopidogrel and better treat them 
before they suffer an ischemic event. Finally, it is virtually impossible to predict which 
individuals will suffer a MI or ischemic stroke using current clinical techniques. A flow 
assay for thrombosis may provide additional predictive capabilities by assessing a specific 
patient’s blood clotting potential. With appropriate identification, higher risk patients may 
be treated and monitored more aggressively than lower risk patients. Ultimately, 
improvements in anti-thrombotic drugs and their use and in patient-specific risk assessment 
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%imageSubtraction_main.m is the calling function for automated thrombus 
%detection. The inputs are: 
%   ref         reference image number (integer)  
%   first       first image to be processed (integer, ref + 1) 
%   last        last image (occlusion) to be processed (integer) 
%   step        step btwn images (integer) 
%   con         conversion factor in px/mm (number) 
%   ROIwidth    width in mm of ROI (number, current working value: 3 mm) 
%   threshPercent   percentage of max intensity difference to identify as  
%    thrombus (number <1, current working value: 0.2) 
%   folder          root folder with images (string) 
%   outputFile      name for .mat save file (string) 
  




metadata = parse_json(string); %parse_json is available from The  






%Read reference image 
I=readColorImage(ref,folder); 
  




%Find capillary edges 
[upperEdge lowerEdge]=findEdge(I1); 
  
%Recrop to same height but with width centered at throat and extending 

















%convert image to 8-bit 
int1=uint8(sum(I1,3)/((2^8-1)*3)*(2^8-1)); 
  










threshold=threshPercent*max(max(Ithresh)); %detect thrombus if pixel 
value is  

















    display(sprintf('Processing image %u',i)) 
    I2=readColorImage(i,folder); 
    I2=imcrop(I2,rect2); 
    Isave{b}=I2; 
     
    int2=brightnessCorrection(I2,I1); 
     
    %image subraction and thresholding 
    I3{a,1}=int2-int1;  
    thromb{a,1}=I3{a,1}>threshold; 
     
    %Calculate thrombus area in plane 
    A(a)=sum(sum(thromb{a,1}));  
         
    %Find thrombus edges    





     
%Volume calculation 
    
V(a)=thrombusVolume(thrombEdgeLower{a},thrombEdgeUpper{a},upperEdge,low
erEdge,con); 
     
    
eval(sprintf('time(%u)=metadata.FrameKey_%u_0_0.ElapsedTime_ms;',a,i)); 
%ms, read from metadata structure 
    a=a+1;  




save(sprintf('%s\\%s',folder,outputFile), 'A', 'V', 'thrombEdgeLower', 








%Reads color image number imNum generated by colorImage.m from folder 
  
if imNum<10 
    I=imread(sprintf('%s\\colorImg_00000000%u.tif',folder,imNum)); 
elseif imNum<100 
    I=imread(sprintf('%s\\colorImg_0000000%u.tif',folder,imNum)); 
elseif imNum<1000 
    I=imread(sprintf('%s\\colorImg_000000%u.tif',folder,imNum)); 
else 






function [upperEdge lowerEdge]=findEdge(I1) 
  


















clear bin  




    if I(i)>size(I1,1)/2 
        lowerI(a,1)=I(i); 
        lowerJ(a,1)=J(i); 
        a=a+1; 
    else 
        upperI(b,1)=I(i); 
        upperJ(b,1)=J(i); 
        b=b+1; 
    end 
end 
         
%Loop through each x-coordinate and find inner most edge point candidate 
for i=min(J):max(J) 
    lowerJtrans=flipud(lowerJ); 
    lowerItrans=flipud(lowerI); 
    [~,loc]=ismember(i,lowerJtrans); 
    if loc~=0 
        lowerEdge(i,2)=lowerItrans(loc); 
        lowerEdge(i,1)=lowerJtrans(loc); 
    end 
     
    [~,loc]=ismember(i,upperJ); 
    if loc~=0 
        upperEdge(i,2)=upperI(loc); 
        upperEdge(i,1)=upperJ(loc); 
    end 






    if size(upperEdge,1)<size(lowerEdge,1) 
        upperEdge(size(upperEdge,1)+1,:)=upperEdge(size(upperEdge,1)-
1,:); 
    elseif size(upperEdge,1)>size(lowerEdge,1) 
        lowerEdge(size(lowerEdge,1)+1,:)=lowerEdge(size(lowerEdge,1)-
1,:); 
    end  
%end 
  




    if lowerEdge(i,2)==0 
        lowerEdge(i,2)=lowerEdge(i-1,2); 
        lowerEdge(i,1)=lowerEdge(i-1,1)+1; 
    end 
    if upperEdge(i,2)==0 
        upperEdge(i,2)=upperEdge(i-1,2); 
        upperEdge(i,1)=upperEdge(i-1,1)+1; 




    if size(upperEdge,1)<size(lowerEdge,1) 
        upperEdge(size(upperEdge,1)+1,:)=upperEdge(size(upperEdge,1)-
1,:); 
    elseif size(upperEdge,1)>size(lowerEdge,1) 
        lowerEdge(size(lowerEdge,1)+1,:)=lowerEdge(size(lowerEdge,1)-
1,:); 
    end  
%end 
  
%fix any outlying points 
for j=1:5 
for i=3:(size(upperEdge,1)-1) 
    if (upperEdge(i,2)-upperEdge(i+1,2))>3 || (upperEdge(i,2)-
upperEdge(i-1,2))>3 
        upperEdge(i,2)=(upperEdge(i+1,2)+upperEdge(i-1,2))/2; 
    end 
    if (lowerEdge(i,2)-lowerEdge(i+1,2))>3 || (lowerEdge(i,2)-
lowerEdge(i-1,2))>3 
        lowerEdge(i,2)=(lowerEdge(i+1,2)+lowerEdge(i-1,2))/2; 











%brightnessCorrection.m returns the brightness-corrected intensity image 
%of I1 based on the brightness of the reference image, ref. 
 
%Calculate mean intensity of reference 
refBright=mean(mean(uint8(sum(ref,3)/((2^8-1)*3)*(2^8-1))));     
 
%Calculate mean intensity of image of interest 
brightMean=mean(mean(uint8(sum(I1,3)/((2^8-1)*3)*(2^8-1))));    
 
%Add the difference in brightness between the images to the image of 
%interest 







%thrombusVolume.m computes the thrombus volume in mm^3 based on the method 
%described in Para (2011) from the lower thrombus boundary, the upper 
%thrombus boundary, upper and lower capillary  boundaries, and the 
%conversion factor (con) in pixels per mm 
  
%Calculated Di and Do 
    Do=(lowerEdge(:,2)-upperEdge(:,2))/con; 
    Di=(lowerThrombEdge-upperThrombEdge)/con; 
     
%Estimated thrombus volume 
Vsub=(Do.^2-Di.^2)/4*pi*1/con; 
for j=1:size(Vsub) 
    if Vsub(j)<0 
        Vsub(j)=0; 








%Converts images captured using micromanager stored in folder to color 
%tifs starting with first image, stepping by step, and ending with last 
%image. Images are saved to a subdirectory 'color' 
  
%Check to see if color folder exists and creat if not 
  
if exist(sprintf('%s\\color',folder),'dir')~=7 




    clear I red green blue rgb 
    %Read image 
    if n<10 
        I=imread(sprintf('%s\\img_00000000%u__000.tif',folder,n)); 
    elseif n<100 
        I=imread(sprintf('%s\\img_0000000%u__000.tif',folder,n)); 
    elseif n<1000 
        I=imread(sprintf('%s\\img_000000%u__000.tif',folder,n)); 
    else 
        I=imread(sprintf('%s\\img_00000%u__000.tif',folder,n)); 
    end 
     
    a=1; 
    %Interpolate color to pixels based on pixelfly documentation 
    for i=1:2:(size(I,1)-4) 
        b=1; 
        for j=1:2:(size(I,2)-4) 
            red(a,b)=(9*I(i+2,j+2)+3*I(i,j+2)+3*I(i+2,j)+I(i,j))/16; 
            green(a,b)=(I(i+1,j+2)+I(i+2,j+1))/2; 
            
blue(a,b)=(9*I(i+1,j+1)+3*I(i+1,j+3)+3*I(i+3,j+1)+I(i+3,j+3))/16; 
            b=b+1; 
        end 
        a=a+1; 
    end 
     
    %Convert to 8bit three-color 
    rgb(:,:,1)=uint8(double(red)/4095*255); 
    rgb(:,:,2)=uint8(double(green)/4095*255); 
    rgb(:,:,3)=uint8(double(blue)/4095*255); 
     
    %display figure and save as tif 
    figure 
    imshow(rgb) 
    if n<10 
        
saveas(gcf,sprintf('%s\\color\\colorImg_00000000%u.tif',folder,n)); 
    elseif n<100 
        
saveas(gcf,sprintf('%s\\color\\colorImg_0000000%u.tif',folder,n)) 
    elseif n<1000 
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saveas(gcf,sprintf('%s\\color\\colorImg_000000%u.tif',folder,n)) 
    else 
        saveas(gcf,sprintf('%s\\color\\colorImg_00000%u.tif',folder,n)) 
    end 




%Repeat for last image (in case last ~= first + n*step) 
clear I red green blue rgb 
if last<10 
    I=imread(sprintf('%s\\img_00000000%u__000.tif',folder,last)); 
elseif last<100 
    I=imread(sprintf('%s\\img_0000000%u__000.tif',folder,last)); 
elseif last<1000 
    I=imread(sprintf('%s\\img_000000%u__000.tif',folder,last)); 
else 




    b=1; 
    for j=1:2:(size(I,2)-4) 
        red(a,b)=(9*I(i+2,j+2)+3*I(i,j+2)+3*I(i+2,j)+I(i,j))/16; 
        green(a,b)=(I(i+1,j+2)+I(i+2,j+1))/2; 
        
blue(a,b)=(9*I(i+1,j+1)+3*I(i+1,j+3)+3*I(i+3,j+1)+I(i+3,j+3))/16; 
        b=b+1; 
    end 









    
saveas(gcf,sprintf('%s\\color\\colorImg_00000000%u.tif',folder,last)); 
elseif last<100 
    
saveas(gcf,sprintf('%s\\color\\colorImg_0000000%u.tif',folder,last)) 
elseif last<1000 
    saveas(gcf,sprintf('%s\\color\\colorImg_000000%u.tif',folder,last)) 
else 










function [lagTime rate]=thrombusRate(folder,file,badIndex,lagThresh, 
outputFile,plotOn) 
  
%Calculates lagTime in sec and rate of thrombus formation in mm3/s from 
%the .mat file generated by imageSubraction_main.m and specified by 
%"folder" and "file." To exclude frames from analysis, include the indices 
%of the bad frames in a vector "badIndex." The lag time threshold 
%(lagThresh) is 0.01 mm3. The arguments are: 
% 
%   folder      folder containing the .mat file for analysis (string) 
%   file        .mat file generated by imageSubtraction_main.m (string) 
%   badIndex    vector containing indices of bad frames, if any (e.g.  
flicker frames, upstream debris, etc.) 
%   lagThresh   threshold of thrombus volume in mm3 below which is  
considered "lag time" (current working value = 0.01 
mm3) 
%   outputFile  name of .mat to save lagTime and rate (enter [] if no  
save is requested 
%   plotOn        binary input for to plot volume vs. time, linear fit of  
thrombus growth after lag time, and lagThresh (1 = plot, 




time=(time-time(1))/1000;     %convert time from ms to sec 
  
%Remove bad points (based on visual image inspection) 
for i=1:numel(badIndex) 
    V(badIndex(i)-(i-1))=[]; 
    time(badIndex(i)-(i-1))=[]; 
end 
  














    figure 
    hold on 
    plot(time,V,'b'); 
    plot(growthTime,polyval(p,growthTime),'r') 
    plot(time,lagThresh*ones(size(time)),'--k') 
    xlabel('Time (s)') 
    ylabel('Thrombus Volume (mm^3/s)') 
    if numel(outputFile)>0 
        saveas(gca,sprintf('%s\\%s.fig',folder,outputFile)); 
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APPENDIX B: MATLAB CODE FOR MICROFLUIDIC IMAGE PROCESSING 
WITH VOLUME INTERPOLATION 






2014-11-18_L023blood+L012plate_control_2\color'; %directory containing  
images to be processed 
startImage=43; %image to start processing 
ref=107;       %image to use as references 
first=ref+1;   %first image to be processed 
last=1506;     %last image to be processed 
step=1;        %step between images processed 
con=202/480;   %length conversion factor pixels per micron 
outputFile='2014-11-18_L023blood+L012plate_control_laterRef'; %output  
file name 
  




metadata = parse_json(string); 
fclose(id); 
eval(sprintf('t0=metadata.FrameKey_%u_0_0.ElapsedTime_ms;',startImage))
; %read t1 from metadata structure 
  













%loop through all images 
for i=first:step:last 
    display(sprintf('Processing image %u',i)) 
     
    %read in, crop, and store raw image 
    I2=readColorImage(i,folder); 
    I=imcrop(I2,rect); 
    Isave{b}=I; 
     
    %convert image to intensity and subtract 
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    int{b}=sum(I,3)/(3*2^8-1); 
    int{b}=imfilter(int{b},s); 
    subtract=int{b}-int1; 
     
    %calculate average thrombus volume using confocal correlation 
    %(pixel-by-pixel) 
    h{b}=(23.731*log(subtract) + 105.73); 
    h{b}(isinf(h{b}))=0; 
    h{b}=h{b}.*double(subtract>0.019)+3.5*double(subtract<=0.019); 
%correlation is height in confocal slices, slice interval = 0.89                      
     
    h{b}=h{b}*0.89; %convert from height in "slices" to height in um 
     
    V(b)=sum(sum(h{b}*con^2,1),2);       %volume in cubic um 
    Vmean(b)=V(b)/(rect(3)*rect(4)*con^2); %average height over area  
(accounts for different ROI) 
     
    %calculate average thrombus volume using confocoal correlation  
%(bulk intensity) 
    VmeanBulk(b)=mean(mean(subtract))*436.83+3.098; %mean height in  
slices 
    VmeanBulk(b)=VmeanBulk(b)*0.89; %convert to mean height in microns 
     
    
eval(sprintf('time(%u)=metadata.FrameKey_%u_0_0.ElapsedTime_ms;',b,i)); 
%ms, read from metadata structure 
    time(b)=time(b)-t0; 
    b=b+1; 
end 






   
APPENDIX C: PROTOCOL FOR PDMS FABRICATION 
A. PDMS Mixing and Pouring 
1. Zero balance with weighing boat and plastic spoon. 
2. Spoon 10-15 g Sylgard 184 base into weighing boat; note the exact mass 
3. Zero balance and add 10% of above mass of curing agent (use disposable 
transfer pipette). 
4. Fold components together until well mixed. 
5. Spoon mixture into clean mold. 
 
B. Degassing 
1. Place filled mold in desiccator and cover with lid. 
2. Open stopcock and turn on vacuum pump. 
3. Tighten stopcock to seal chamber. Run vacuum pump until top of PDMS is 
bubbly. Tightly seal stopcock and turn off pump. 
4. Let degas for 20 minutes. 
5. Open stopcock to release vacuum and remove mold. Any remaining bubbles 
can be popped with toothpick or blown away. 
 
C. Curing 
1. Place degassed mold in oven at 120°C for 20 minutes. Be careful not to over-
cure either by increasing the temperature or extending the time as the PDMS 
will become brittle and crack when inserting connectors. 
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2. Test doneness with toothpick away from channel area; should be solid/does 
not indent or form peak. 
3. Let cool 20 minutes. 
4. Use X-ACTO knife to separate the perimeter of the chip from the mold. Lift 
on corner up and carefully peel away the chip. 
 
D. Punching 
1. Sharpen a 16 gauge blunt needle using rotary tool; use grinding stone and 
speed stetting 5. 
Green = 14 gauge, magenta = 16 gauge, pink = 18 gauge 
1. With the feature side up, carefully use the needle tip to punch holes at each 
end of the test sections. 
2. Use an 18 gauge blunt needle to pop out the punches. 
3. Use Scotch tape to clean surfaces and seal both sides if stored. 
4. *Note: If chip is to be bonded to cover glass, trim chip to size.  
 
E. Bonding 
1. Power on plasma cleaning; wait 1.5 minutes for warm up 
2. Place chip and microscope slide/cover glass in chamber with bonding sides 
up. 




4. Turn RF to high. Use needle valve to bleed in atmospheric air so color is 
bright magenta (between blue and violet). 
5. Turn pump and RF off. Slowly bleed air back in and remove cover. 
6. Quickly align and bond slide and chip; you have ~20 sec. 
7. Turn off plasma cleaner. 
8. Cure chip at 70°C for 1 hr. After cooling, cover with Scotch tape to keep clean 
and allow to rest overnight. 
 
F. Collagen Coating (24 hrs before experiment) 
1. Dilute stock Chronolog collagen 9:1 with saline. For 1 chip, make 50 μL 
solution (45 μL saline, 5 μL stock collagen). 
2. Gently pipet 2.5 μL solution into each channel. 
3. Seal in Tupperware with warm, moist paper towel. 




APPENDIX D: WASHED RED BLOOD CELL PREPARATION 
Adapted from a protocol from the Emory Genetics Laboratory. 
 
MATERIALS 
Normal saline (0.9% w/v NaCl) 
 
METHODS 
1. Collect blood in anticoagulant of choice (heparin, citrate, etc.). Heparin (15.8 USP 
units/mL) was used in this dissertation. 
2. Transfer 8 mL of blood into 15 mL centrifuge tubes. 
3. Centrifuge for 5 minutes at 1800g (9 notches on Fisher Scientific CentrificTM 
Centrifuge). Make sure to balance the centrifuge. 
4. Pipette off supernatant using either transfer pipet or micropipette. 
5. Add normal saline to 8 mL. Mix saline and red blood cells by pipetting up and 
down. 
6. Centrifuge for 5 minutes at 1200 g (6 notches on Fisher Scientific CentrificTM 
Centrifuge). 
7. Repeat steps 4-6 once, or until supernatant is clear. 
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APPENDIX E: PLATELET ISOLATION PROTOCOL 





Molar Concentrations Mass in 250 mL solution 
39 mM citric acid 1.87 g citric acid 
75 mM sodium citrate 4.84 g sodium citrate 
135 mM dextrose 6.08 g dextrose 
 
Sodium citrate is an anticoagulant that acts by chelating calcium ions, which are 
essential cofactors in the coagulation cascade. Calcium chelation also reduces 
platelet activation. Citric acid reduces the pH of the solution, which future inhibits 
platelet activation. Preventing platelet activation is critical for isolating platelets via 






Molar Concentrations Mass in 250 mL solution 
134 mM NaCl 1.96 g NaCl 
12 mM NaHCO3 0.25 g NaHCO3 
2.9 mM KCl 0.05 KCl 
1 mM MgCl2 0.03 MgCl2
 + 6H2O (check hydrate and adjust 
as needed)  
10 mM HEPES 0.6 g HEPES 
 
Bovine serum albumin (BSA) OR human serum albumin (HSA 
Dextrose 
 
For day of use: 
Tyrode’s albumin buffer: combine 10 mL Tyrode’s buffer, 0.001 g glucose, and 
1 mL BSA or HSA 
 
METHODS 
1. Collect blood in 6:1 ACD 
2. Transfer 14 mL into 15 mL centrifuge tubes. 
3. Centrifuge at 250g (2.7 notches on Fisher Scientific CentrificTM Centrifuge) for 
16 minutes. Make sure to balance the centrifuge. 
4. Very gently pipette off the platelet-rich plasma (PRP) using micropipette and 
transfer into new centrifuge tubes. 
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5. Add 10% by volume ACD to PRP. 
6. Centrifuge at 2200g (8 notches on Fisher Scientific CentrificTM Centrifuge) for 13 
minutes. 
7. Pipette off the supernatant. 
8. Resuspend platelet pellet in Tyrode’s albumin buffer by gently pipetting up and 
down. Volume of resuspending buffer depends on desired platelet count. As an 
estimate, platelet yield will be about 10% of total platelets in plasma sample. 
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